BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com
## Progress in Voluntary Medical Male Circumcision for HIV Prevention

Supported by the United States President’s Emergency Plan for AIDS Relief through 2016: 10 Years of Program Data

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2018-021835</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Research</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>22-Jan-2018</td>
</tr>
</tbody>
</table>

**Complete List of Authors:**
- Davis, Stephanie; US Centers for Disease Control and Prevention
- Hines, Jonas; US Centers for Disease Control and Prevention
- Habel, Melissa; US Centers for Disease Control and Prevention
- Grund, Jonathan; US Centers for Disease Control and Prevention
- Ridzon, Renee; Office of the US Global AIDS Coordinator
- Baack, Britney; US Centers for Disease Control and Prevention
- Davitte, Jonathan; US Department of Defense, Naval Health Research Center
- Thomas, Anne; US Department of Defense, Naval Health Research Center
- Kiggundu, Valerian; United States Agency for International Development
- Bock, Naomi; US Centers for Disease Control and Prevention
- Pordell, Paran; US Centers for Disease Control and Prevention
- Cooney, Caroline; Office of the US Global AIDS Coordinator
- Toledo, Carlos; US Centers for Disease Control and Prevention

**Keywords:** Public health < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, PREVENTIVE MEDICINE
Progress in Voluntary Medical Male Circumcision for HIV Prevention
Supported by the United States President’s Emergency Plan for AIDS Relief through 2016:
10 Years of Program Data

Stephanie M. Davis¹, Jonas Hines¹, Melissa Habel¹, Jonathan M. Grund¹, Renee Ridzon², Brittney Baack³, Jonathan Davitte⁴, Anne Thomas⁴, Valerian Kiggundu⁵, Naomi Bock¹, Paran Pordell³, Caroline Cooney², Carlos Toledo¹

1: US Centers for Disease Control and Prevention, Division of Global HIV and TB, HIV Prevention Branch, Voluntary Medical Male Circumcision Team, Atlanta, GA
2: Office of the U.S. Global AIDS Coordinator and Health Diplomacy, President’s Emergency Plan for AIDS Relief, Washington, DC
3: US Centers for Disease Control and Prevention, Division of Global HIV and TB, Monitoring, Evaluation, and Data Analytics Branch, Clinical Monitoring and Evaluation Team, Atlanta, Georgia
4: Naval Health Research Center, US Department of Defense HIV/AIDS Prevention Program (DHAPP), San Diego, CA
5: United States Agency for International Development, Washington, DC

Corresponding author:

Stephanie M. Davis, MD, MPH
vic6@cdc.gov

Word Count: 2921
PEPFAR circumcisions through 2016

ABSTRACT:

OBJECTIVE This article provides an overview and interpretation of the performance of PEPFAR’s male circumcision program, which has supported the majority of voluntary medical male circumcisions performed for HIV prevention, from its 2007 inception through 2016, and client characteristics in 2016.

DESIGN Longitudinal collection of routine program data and disaggregations.

SETTING 14 countries in sub-Saharan Africa with low baseline male circumcision coverage, high HIV prevalence, and PEPFAR-supported voluntary medical male circumcision programs.

PARTICIPANTS Clients of PEPFAR-supported voluntary medical male circumcision programs directed at males aged 10 years and above.

MAIN OUTCOME MEASURES Numbers of circumcisions performed and disaggregations by age band, HIV test uptake and result, procedure technique, and follow-up visit attendance.

RESULTS PEPFAR supported a total of 11,886,276 circumcisions in 14 countries in southern and eastern Africa. In 2016, 46% of clients were under 15 years of age, 9% were not tested for HIV and 1% of those tested were HIV+, and 78% returned for a follow-up visit within 14 days of circumcision.

CONCLUSIONS Recruiting older, sexually active clients continues to be a challenge despite targeted efforts. The substantial proportion of clients not testing for HIV is expected and may be reassuring that testing is not being presented as mandatory for access to circumcision. While VMMC is extremely safe, achieving the highest possible follow-up rates for early diagnosis and intervention on complications is crucial, and programs continue to work to raise follow-up rates. The VMMC program has achieved rapid scaleup but continues to face challenges, and new approaches may be needed to achieve the new UNAIDS goal of 27 million additional circumcisions through 2020.
PEPFAR circumcisions through 2016

STRENGTHS AND LIMITATIONS OF THIS STUDY:

- The large dataset covers ten years of virtually complete program data on nearly 12 million men.
- PEPFAR-supported clients constitute a large majority of all voluntary medical male circumcision clients, making client characteristics reported here likely to be representative of the program as a whole.
- The multicountry nature of the data allows determination of client characteristics common across settings.
- The routine reporting system is aggregate only, and collected data does not support analyses of associations between client characteristics.
- Data are not complete for all client characteristics (disaggregations) in all countries.
INTRODUCTION:

Male circumcision, the removal of the foreskin, reduces a man’s risk of acquiring HIV through heterosexual exposure by approximately 60 percent. Since its adoption as a recommended HIV prevention strategy by the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) in 2007, voluntary medical male circumcision (VMMC) has become a core component of the global HIV prevention portfolio through support by national and global programs, such as the United States (U.S.) President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The WHO/UNAIDS’s guiding document for VMMC from 2012-2016 recommended scale-up of VMMC in 14 countries in southern and eastern Africa with high HIV prevalence, low circumcision coverage and primarily heterosexual HIV transmission, with an initial goal of circumcising 20 million men to achieve 80% coverage among males aged 15-49 years in the 14 countries by 2016. As a one-time biomedical intervention conferring lifelong partial protection from HIV, and the only prevention method specifically targeted at HIV-negative heterosexual men, VMMC complements other behavioral and clinical prevention interventions such as condom promotion, reduction in number of sex partners, pre-exposure prophylaxis, and treatment-as-prevention.

VMMC services were launched progressively in each of the recommended 14 countries between 2007 and 2011, primarily with PEPFAR support. PEPFAR-supported VMMCs are surgical or procedural interventions often lasting 5-15 minutes, provided by physicians or nurses under local anesthesia. They are offered with the WHO-recommended minimum package of accompanying services, including the offer of HIV testing and linkage to care and treatment for HIV-positive individuals, HIV risk-reduction education, condom provision, and sexually transmitted infection (STI).
PEPFAR circumcisions through 2016

screening and treatment or referral. Over the lifetime of the program, several additional key innovations have also been incorporated. These include the introduction of WHO-prequalified circumcision devices as alternatives to conventional surgery; the introduction of WHO “Models for Optimizing Volume and Efficiency”\(^8\); the identification of the 15-29 year age group as the focal demographic for rapidly reducing population-level HIV incidence through VMMC\(^9\); enhancement of safety measures based on accumulating data, particularly for adolescents based on their unique surgical safety requirements; introduction of policies on tetanus vaccination prior to VMMC\(^10\); and increased emphasis on linking clients testing HIV-positive to care and treatment\(^11\) to support WHO/UNAIDS treatment scale-up goals\(^12\).

All PEPFAR-supported VMMC programs report on key program outcomes, including the total VMMCs performed in each country and select disaggregations: circumcision technique (device or surgical), client age range, HIV test results among VMMC clients tested at VMMC sites, and adherence to routine post-operative follow-up. These indicators provide an overview of the accomplishments and key current attributes of the PEPFAR VMMC program. This article presents PEPFAR-supported VMMC achievements since program inception in 2007, compares key disaggregations from U.S. fiscal year 2016 with those from 2015, and discusses future challenges and directions for the program. Because PEPFAR supports the majority of VMMCs conducted globally (approximately 82\% through 2016)\(^13\), client characteristics described here are expected to be reasonably representative of the global VMMC clientele to date.
PEPFAR circumcisions through 2016

METHODS:

Data reported by PEPFAR-supported VMMC programs are drawn initially from site-level client registers and records, and reported by the implementing partners to PEPFAR in each host country. Data are then cleaned in-country; and then reported to PEPFAR’s central coordinating body, the Office of the Global AIDS Coordinator. Implementing partners also report to their host country governments, following procedures agreed upon in-country; this may occur independently or may use the same data stream. Data are currently reported to PEPFAR on a quarterly basis, and then grouped by U.S. Government fiscal year, which runs October 1st through September 30th, rather than by calendar year. These numerical data are now available online and were used here to calculate percentages where relevant. Monitoring trends across years is possible, but prior to 2015, fewer VMMC disaggregations were collected.

The disaggregations reported for VMMCs performed, and definitions where needed, are listed in table 1. Their rationales and context are summarized below.
Table 1: Disaggregations and Categories for PEPFAR-supported VMMC program reporting on VMMCs performed, 2016

<table>
<thead>
<tr>
<th>Disaggregation</th>
<th>Client Categories</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&lt; 61 days (early infant male circumcision)</td>
</tr>
<tr>
<td></td>
<td>- 2 months-&lt;10 years (not funded by PEPFAR due to safety concerns)</td>
</tr>
<tr>
<td></td>
<td>- 10-14 years</td>
</tr>
<tr>
<td></td>
<td>- 15-19 years</td>
</tr>
<tr>
<td></td>
<td>- 20-24 years</td>
</tr>
<tr>
<td></td>
<td>- 25-29 years</td>
</tr>
<tr>
<td></td>
<td>- 30-49 years</td>
</tr>
<tr>
<td></td>
<td>- 50+ years</td>
</tr>
<tr>
<td>Result of HIV test offer at VMMC site</td>
<td>HIV+</td>
</tr>
<tr>
<td></td>
<td>- HIV -</td>
</tr>
<tr>
<td></td>
<td>- Unknown: includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason</td>
</tr>
<tr>
<td>Technique</td>
<td>Surgical</td>
</tr>
<tr>
<td></td>
<td>Device-based</td>
</tr>
<tr>
<td>Post-operative Follow-up status</td>
<td>Returned for at least one post-operative follow-up visit within 14 days of surgery</td>
</tr>
<tr>
<td></td>
<td>- Did not return within 14 days</td>
</tr>
</tbody>
</table>

1) **Client age category**: PEPFAR’s prioritization of, or “age pivot” to, the 15-29 year age range began in fiscal year 2016. Ages below 15 years constitute the largest combined proportion of VMMCs performed, but will have delayed impact on the HIV epidemic due to the delay until sexual debut and other risk behaviors. These age bands are collapsed together in this report.

2) **Result from client HIV test offered at VMMC site**: Under PEPFAR¹⁵, UNAIDS¹⁶ and WHO¹⁷ guidance active in 2016, HIV testing at the VMMC site should be encouraged but is not required for access to VMMC, and clinically eligible clients choosing to test may proceed with VMMC regardless of their test results. As a disaggregation within the cohort of clients receiving VMMC, this reporting does not include men who were tested at VMMC sites but
then decided against VMMC after receiving a positive HIV test result, as men testing positive are counseled that circumcision will not affect the course of their HIV infection and may choose not to proceed.

3) Circumcision technique used: Circumcision devices offer an alternative to surgery, and advantages include faster procedures and potentially avoiding the injection of anesthesia and incision of living tissue. Initially, PEPFAR-supported circumcision was exclusively surgical, using one of three WHO-recommended techniques: forceps-guided, dorsal slit, and sleeve resection. With WHO prequalification of the PrePex device in 2013 and ShangRing in 2015, some ministries of health have introduced device-based services as additional options for clients. Both PrePex and ShangRing devices remain on the penis for seven days and are removed by a provider during a follow-up visit. Anatomic and age-based eligibility criteria vary between devices and can be stricter than surgical eligibility criteria, restricting the pool of eligible clients. Numbers of circumcisions performed using a device therefore reflect national policies and eligibility for, as well as availability and client uptake of, these alternative methods. They also reflect the impact of tetanus mitigation policies as discussed below.

4) Follow-up status: PEPFAR-supported programs follow fixed schedules for routine postoperative follow-up set by national ministries of health to ensure client safety. These often include a return visit at days two and seven after surgery, or day seven after device placement (for device removal). In 2016, the PEPFAR follow-up indicator was only reported among surgical cases, which therefore constitute the denominator for determining follow-up percentage.
PEPFAR circumcisions through 2016

RESULTS:

From PEPFAR fiscal year 2007 through 2016, a total of 11,886,276 PEPFAR-supported VMMCs were performed in 14 countries in southern and eastern Africa. From 2010 through 2014, annual VMMC numbers approximately doubled annually, reaching 2,794,808 in 2014. In 2015, 2,573,273 VMMCs were performed, followed in 2016 by 2,290,200; these represented the second- and third-highest annual totals. Nearly two thirds (64%) of PEPFAR-supported circumcisions performed since the program’s inception were performed in 2014-2016 (Figure 1, Table 2). In 2016, PEPFAR-supported VMMCs constituted 80% of all VMMCs reported by WHO, and 55% or more of reported VMMCs in all individual countries except Rwanda.13
PEPFAR circumcisions through 2016

Table 2: Annual PEPFAR-funded VMMCs performed by country, 2007-2016*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>5,180</td>
<td>534</td>
<td>0</td>
<td>8,590</td>
<td>12,464</td>
<td>13,893</td>
<td>7,712</td>
<td>24,201</td>
<td>72,574</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>0</td>
<td>3,110</td>
<td>8,236</td>
<td>12,445</td>
<td>16,393</td>
<td>11,831</td>
<td>11,307</td>
<td>14,335</td>
<td>77,657</td>
</tr>
<tr>
<td>Kenya</td>
<td>45,657</td>
<td>112,574</td>
<td>182,788</td>
<td>158,278</td>
<td>214,851</td>
<td>229,390</td>
<td>233,813</td>
<td>264,490</td>
<td>1,441,841</td>
</tr>
<tr>
<td>Lesotho</td>
<td>0</td>
<td>0</td>
<td>199</td>
<td>6,971</td>
<td>36,418</td>
<td>39,175</td>
<td>28,909</td>
<td>31,709</td>
<td>143,381</td>
</tr>
<tr>
<td>Malawi</td>
<td>0</td>
<td>0</td>
<td>778</td>
<td>13,314</td>
<td>67,384</td>
<td>68,334</td>
<td>90,820</td>
<td>82,381</td>
<td>323,011</td>
</tr>
<tr>
<td>Mozambique</td>
<td>0</td>
<td>4,009</td>
<td>18,946</td>
<td>79,002</td>
<td>129,581</td>
<td>160,660</td>
<td>187,186</td>
<td>241,793</td>
<td>821,177</td>
</tr>
<tr>
<td>Namibia</td>
<td>117</td>
<td>1,229</td>
<td>5,379</td>
<td>6,121</td>
<td>0**</td>
<td>785</td>
<td>9,927</td>
<td>15,116</td>
<td>38,674</td>
</tr>
<tr>
<td>Rwanda</td>
<td>0</td>
<td>896</td>
<td>3,922</td>
<td>17,639</td>
<td>36,441</td>
<td>74,803</td>
<td>65,048</td>
<td>50,204</td>
<td>248,953</td>
</tr>
<tr>
<td>South Africa</td>
<td>18,100</td>
<td>14,956</td>
<td>72,004</td>
<td>170,849</td>
<td>294,977</td>
<td>327,473</td>
<td>472,047</td>
<td>355,917</td>
<td>1,726,323</td>
</tr>
<tr>
<td>Swaziland</td>
<td>3,802</td>
<td>19,728</td>
<td>13,399</td>
<td>14,456</td>
<td>9,708</td>
<td>11,934</td>
<td>12,156</td>
<td>16,003</td>
<td>101,186</td>
</tr>
<tr>
<td>Tanzania</td>
<td>262</td>
<td>21,581</td>
<td>117,351</td>
<td>151,915</td>
<td>381,394</td>
<td>554,673</td>
<td>615,089</td>
<td>519,437</td>
<td>2,361,702</td>
</tr>
<tr>
<td>Uganda</td>
<td>0</td>
<td>9,052</td>
<td>57,132</td>
<td>352,039</td>
<td>742,978</td>
<td>906,615</td>
<td>466,650</td>
<td>330,343</td>
<td>2,864,809</td>
</tr>
<tr>
<td>Zambia</td>
<td>0</td>
<td>21,236</td>
<td>63,444</td>
<td>103,517</td>
<td>199,372</td>
<td>239,464</td>
<td>216,394</td>
<td>185,028</td>
<td>1,028,455</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>0</td>
<td>9,811</td>
<td>30,608</td>
<td>36,765</td>
<td>88,114</td>
<td>155,778</td>
<td>156,215</td>
<td>159,243</td>
<td>636,534</td>
</tr>
<tr>
<td>Total</td>
<td>73,118</td>
<td>218,716</td>
<td>574,186</td>
<td>1,131,900</td>
<td>2,230,075</td>
<td>2,794,808</td>
<td>2,573,273</td>
<td>2,290,200</td>
<td>11,886,276</td>
</tr>
</tbody>
</table>

* Fiscal years

** PEPFAR support for VMMC in Namibia was paused for strategic planning in 2013.
PEPFAR circumcisions through 2016

Twelve countries provided >85% data completeness across all disaggregations in 2016. Where data completeness for a given disaggregate in a country (sum of all VMMCs across categories for that disaggregate, divided by total VMMCs performed) was less than the 85% threshold we selected for this analysis, values are bolded (Table 3).

In total, 46% of VMMC clients were within the 15-29 years age range, to which PEPFAR shifted focus that year, down from 48% in 2015, with wide variation among countries, ranging from 32% in Swaziland to 85% in Rwanda. In contrast, 46% of PEPFAR VMMC clients were within the 10-14 years range, up from 42% in 2015. Of the 13 countries reporting age data for 2015 and 2016, 10 experienced an increase in the proportion of males circumcised in the 10-14 year age group between 2015 and 2016. Among high-volume programs, this shift toward circumcision of 10-14 year olds was largest in Kenya (48% in 2015, then 56% in 2016) and Tanzania (45% in 2015, then 52% in 2016).
### Table 3: Numbers and Characteristics of PEPFAR-funded Voluntary Medical Male Circumcisions, Fiscal Year 2016 (Oct. 1, 2014-Sept 30, 2016) by country and 2015 totals

<table>
<thead>
<tr>
<th>Country</th>
<th>VMMCs</th>
<th>Client Age in Years (%)*</th>
<th>HIV status (%)</th>
<th>Device Method Used (%) (vs. Surgical)</th>
<th>Follow-up Visit **(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;15 15-19 20-24 25-29 30-49 50+</td>
<td>HIV+ among tested clients Unknown *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Botswana</td>
<td>24,201</td>
<td>45 15 14 11 14 1</td>
<td>4 33 28</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>Ethiopia</td>
<td>14,335</td>
<td>32 34 18 7 9 0</td>
<td>0 48 7</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>264,490</td>
<td>56 26 9 5 3 0</td>
<td>3 32 1</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Lesotho</td>
<td>31,709</td>
<td>56 22 8 6 8 1</td>
<td>3 6 3</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>Malawi</td>
<td>82,381</td>
<td>49 30 10 5 5 0</td>
<td>5 31 0</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Mozambique</td>
<td>241,793</td>
<td>42 32 14 6 5 0</td>
<td>0 0 0</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>15,116</td>
<td>12 32 20 15 20 2</td>
<td>1 0 0</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>Rwanda</td>
<td>50,204</td>
<td>5 46 27 12 9 0</td>
<td>1 0 53</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>355,917</td>
<td>51 19 10 8 11 1</td>
<td>1 12 1</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Swaziland</td>
<td>16,003</td>
<td>65 22 7 3 3 1</td>
<td>1 5 5</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>Tanzania</td>
<td>519,378</td>
<td>52 26 11 5 6 0</td>
<td>0 14 0</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>330,343</td>
<td>38 27 13 8 8 7</td>
<td>1 2 3</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>Zambia</td>
<td>185,028</td>
<td>34 28 17 11 9 1</td>
<td>3 17 0</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>159,243</td>
<td>37 30 13 9 10 1</td>
<td>0 7 27</td>
<td>107***</td>
<td></td>
</tr>
<tr>
<td>Total in 2016</td>
<td>2,290,141</td>
<td>46 27 12 7 7 1</td>
<td>1 9 4</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Total in 2015</td>
<td>2,573,238</td>
<td>42 28 13 7 8 1</td>
<td>1 7 5</td>
<td>72</td>
<td></td>
</tr>
</tbody>
</table>

**Bolded** entries indicate <85% data completeness.
* Includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason
** Percent of clients who returned for at least one post-operative follow-up visit within 14 days of surgery
*** In some countries, reported numerators may not have been confined to surgical followup visits as intended, inflating followup rates even above 100%.
PEPFAR circumcisions through 2016

Overall, 9% of clients had “unknown” HIV status, as compared to 7% in 2015, with individual country values ranging between 0% in Rwanda and 48% in Ethiopia. Among clients tested for HIV, 1% were positive, essentially unchanged from 2015, with individual country positivity varying between 0% in Zimbabwe, Tanzania, Mozambique and Ethiopia, and 5% in Malawi.

Device-based circumcision techniques constituted a small percentage of circumcisions in all countries in 2016, accounting for 4% of VMMCs across countries (down from 5% in 2015), ranging between 0% in several countries and 53% in Rwanda, with Botswana and Zimbabwe following at 28% and 27%, respectively.

Post-operative follow-up rates were 78% overall, an increase from 72% in 2015. These ranged between 50% in South Africa and 107% in Zimbabwe, falling at or above 75% in 11 countries. Because follow-up reporting in 2016 was based on percent of surgical clients only who returned for follow-up, calculated follow-up rates may be lower than true rates in countries with substantial numbers of device-based VMMCs, which would be expected to have high follow-up due to the necessity of returning to remove the device. However, in some countries, reported numerators may not have been confined to surgical follow-up visits as intended, inflating reported follow-up rates even above 100%.

**CONCLUSION:**

VMMC has undergone a scale-up of historic proportions within global health, comparable to the scale-up of HIV treatment. Nearly 12 million PEPFAR-supported VMMCs were performed, out of a sub-Saharan African total of nearly 15 million, between 2007 when support began and 2016, making
PEPFAR circumcisions through 2016

VMMC an essential prevention intervention for achieving the PEPFAR goal of an AIDS-free generation through epidemic control in sub-Saharan Africa. Models estimate that global VMMCs conducted through 2016 will avert 500,000 infections by the end of 2030. Scale-up has been enabled not only by dedicated resources, totaling over $1.5 billion through 2016 from PEPFAR alone, but also through leadership from ministries of health, rapid expansion of surgical skills and responsibilities to non-physician health cadres, and public outreach campaigns. It has provided millions of men with lifelong partial protection from HIV and some STIs, and connected them with additional HIV and other health services through testing, STI screening, and referrals for other health conditions. Infections averted in men through VMMC also help prevent new HIV infections among women and girls, and male circumcision is also associated with lower prevalence of a range of STIs in women.

PEPFAR committed in 2015 to supporting at least 13 million VMMCs through 2017, and has remained on track to achieve that target. In light of the high proportion of global VMMCs supported, PEPFAR client data is also expected to provide a reasonably representative view of the global VMMC clientele to date. References to achievements and characteristics below refer to the PEPFAR program except where otherwise stated.

All VMMC implementing countries continue to scale up VMMC. However, in 2015 and 2016 there were substantial declines in PEPFAR VMMC achievements in Uganda (the largest contributor to VMMC results); these were mirrored by declines in total VMMCs achieved in Uganda. Service delivery and policy were impacted by the identification of tetanus as a risk among VMMC clients in the Ugandan setting, due to limited historical tetanus immunization coverage. WHO issued global recommendations that additional visits for tetanus vaccination be performed prior to circumcision using device-based VMMC methods associated with increased risk of tetanus, and the Uganda National
PEPFAR circumcisions through 2016

VMMC Program ultimately required an additional visit for tetanus vaccination prior to VMMC. This shift may have also impacted performance in several other countries. Additionally, a PEPFAR policy issued in late 2014 discontinued the use of the forceps-guided surgical technique in young adolescents to avoid the associated risk for injury to the immature glans, causing some country programs to decrease VMMC provision to this age group until they could retrain their VMMC workforces in a more appropriate method. In 2016, Tanzania, South Africa and Zambia also experienced declines, possibly due to these same reasons, some exhaustion of their ‘early adopter’ populations, and strategic shifts in program geography and funding.

VMMC client populations in 2016 were young, with males aged 10-14 years representing 46% of all PEPFAR VMMCs (virtually all VMMCs in clients <15 years are in the 10-14 year range), as compared to 12% of the combined male general population of the 14 implementing countries.33 This represents a change from the program’s historical client age distribution; from 2010 through 2013, clients in the 10-14 years age range characterized no more than one third of all clients in any year.34 The 2015 distribution (42% of clients were aged <15 years) served as the baseline prior to implementation of the “age pivot”; yet the actual age balance shifted further toward the younger range in 2016 despite this focus. In some countries, this shift may partially reflect the maturation of the VMMC program: ‘exhaustion’ of this age band and replacement with younger males.

VMMC clients also have low HIV positivity compared to the general population, 1.2%, vs. 5.5 (95% confidence interval 4.9-6.0% prevalence among males aged 15-49 years in the southern and eastern Africa region in 2016.35 The young age of the client population is almost certainly the major underlying factor; pre-adolescents and early adolescents have less exposure to sex and consequently less HIV risk and lower HIV prevalence than older age groups. Because HIV test results are not
PEPFAR circumcisions through 2016

disaggregated by age group, this effect cannot be controlled for in PEPFAR routine reporting data.
Lower HIV prevalence among VMMC clients could also reflect self-selection of men with health-
protecting behaviors into the pool of VMMC clients and/or the effects of messaging promoting VMMC
for HIV prevention, leading to the self-exclusion of men who know they are HIV-positive (including
any who learn they are HIV-positive at the VMMC site and consequently opt out of VMMC). Despite
this low prevalence, it should be noted that men in sub-Saharan Africa have lower HIV testing uptake
than women\(^\text{36}\) and the VMMC program provides an opportunity to reach men who might not otherwise
undergo testing. The substantial proportion of clients with ‘unknown’ test results is expected, and is
likely to reflect the voluntary nature of HIV testing in VMMC, as well as the frequency of HIV test kit
stockouts.

The fact that only 4% of all 2016 circumcisions were performed by device methods reflects the
relatively short period that device-based circumcision has been available, as well as the rigorous
country-level vetting process which new devices undergo when being introduced in a new country,\(^\text{37}\)
prior to nationwide rollout. It may also reflect current preferences of clients and programs. As of
publication, all countries implementing PEPFAR-supported VMMC except Ethiopia and Namibia have
begun the evaluation process for at least one device, although scale-up of device-based service delivery
can take time even after evaluation is completed and policy is in place. Although devices offer several
advantages over surgical circumcision, they require more intense post-market safety monitoring tailored
to their mechanisms of action, until more VMMCs have been done using these methods. Most recently,
takeup of the most commonly-used device has also been negatively impacted by the WHO advice and
PEPFAR policy related to tetanus vaccination prior to device placement.\(^\text{38}\)
PEPFAR circumcisions through 2016

Most countries with low follow-up proportions also have low follow-up data completeness, making these results difficult to interpret. However, there is evidence that adverse events (AEs) are actually more common among males who do not return for follow-up than among those who do.\(^{39}\) While VMMC is extremely safe,\(^{40}\) achieving high follow-up rates to allow early AE diagnosis and intervention is crucial for program safety.

The findings in this paper are subject to several limitations. These data reflect results supported by PEPFAR, rather than country totals. Additionally, cross-tabulations between disaggregations are not reported, and therefore it is not possible to determine associations between age group, HIV status and procedure technique. Data are not complete for all disaggregations in all countries. Data entry errors such as those discussed above for followup, and variations in reporting practice, are possible. Category definitions combine some disparate groups (e.g. “unknown” test results include men who were not tested at VMMC sites for any reason, whether preference, test kit shortage, or documentation of recent outside testing.)

The global VMMC program’s achievements to date have demonstrated the feasibility of rapid scale-up of circumcision coverage, but program strategy will need to continue evolving to maximize impact, achieve revised targets, maintain safety, and meet broader UNAIDS and PEPFAR objectives. Attracting more 15-29-year-old clients, and ideally other high-risk clients who will benefit most from VMMC, may require new demand creation approaches and service delivery models. Though current achievements have passed the halfway mark to the initial global target, this target was recently revised under the new UNAIDS Fast Track framework to include 27 million additional circumcisions by the end of 2020 beyond those conducted through 2015,\(^{41}\) to reach 90% coverage among 10-29-year-olds.\(^{42}\) Reaching these VMMC targets is a key component of the Fast Track strategy: the overall impact

17
PEPFAR circumcisions through 2016

projection for achievement of Fast Track goals – 28 million HIV infections averted by 2030 – depends in part on achieving and maintaining this coverage. Finally, the updated 2016 WHO/UNAIDS framework for VMMC calls for circumcision programs to shift from largely stand-alone service delivery toward greater integration within a broad platform of adolescent and adult male reproductive health. Strategies that reached “early adopters” predisposed to uptake VMMC rapidly may differ from those needed to reach the remaining uncircumcised men, and to do so within this integrated platform. To achieve the ambitious goals in this framework, substantial engagement and increased resource commitments from stakeholders other than PEPFAR, including national ministries of health, will be needed.

FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sections. It was supported in part by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).

COMPETING INTERESTS: Authors declare no competing interests.

DISCLAIMER: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies, the Centers for Disease Control and Prevention, the US Agency for International Development, or the United States Government.
PEPFAR circumcisions through 2016

CONTRIBUTORSHIP: Stephanie M. Davis drafted and finalized the manuscript.
Jonas Hines, Melissa Habel, Jonathan M. Grund, Renee Ridzon, Jonathan Davitte, Anne Thomas, Valerian Kiggundu, Caroline Cooney, and Naomi Bock revised the manuscript.
Brittney Baack and Paran Pordell revised the data and manuscript.
Carlos Toledo conceived of the paper, obtained the data, and revised the manuscript.

DATA SHARING: As described in this article, the dataset underlying the tables and results is publicly available at https://data.pepfar.net/quarterlyData/.

ETHICAL STATEMENT: Use of this routinely collected, aggregate-only program data was reviewed and approved by CDC Human Subjects Protection.

RESEARCH REPORTING CHECKLISTS: Because this manuscript is based on routinely collected program data and does not examine associations between risk factors and outcomes, none of the standard checklists are applicable, including per EquatorWizard.
PEPFAR circumcisions through 2016
PEPFAR circumcisions through 2016

Figure Legend

**Figure 1:** Cumulative Number of PEPFAR-supported Voluntary Medical Male Circumcisions by Country, 2007-2016
REFERENCES


PEPFAR circumcisions through 2016

14 PEPFAR. “Quarterly Results.” Accessed online at https://data.pepfar.net/quarterlyData/ on October 26, 2017.
PEPFAR circumcisions through 2016


29 Uganda Ministry of Health. Memo Re: The need for tetanus vaccination for men undergoing circumcision and the continued scale-up of safe male circumcision using PrePex.” December 30, 2015.


24
PEPFAR circumcisions through 2016

**Figure 1:**

Cumulative Number of PEPFAR-Supported Voluntary Medical Male Circumcisions by Country, 2007-2016

* Fiscal years
Progress in Voluntary Medical Male Circumcision for HIV Prevention  
Supported by the United States President’s Emergency Plan for AIDS Relief through 2017: Longitudinal and Recent Cross-sectional Program Data

<table>
<thead>
<tr>
<th>Journal</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2018-021835.R1</td>
</tr>
<tr>
<td>Article Type</td>
<td>Research</td>
</tr>
<tr>
<td>Date Submitted by the Author</td>
<td>30-Apr-2018</td>
</tr>
<tr>
<td>Complete List of Authors</td>
<td>Davis, Stephanie; US Centers for Disease Control and Prevention, Hines, Jonas; US Centers for Disease Control and Prevention, Habel, Melissa; US Centers for Disease Control and Prevention, Grund, Jonathan; US Centers for Disease Control and Prevention, Ridzon, Renee; Office of the US Global AIDS Coordinator, Baack, Brittney; US Centers for Disease Control and Prevention, Davitte, Jonathan; US Department of Defense, Naval Health Research Center, Thomas, Anne; US Department of Defense, Naval Health Research Center, Kiggundu, Valerian; United States Agency for International Development, Bock, Naomi; US Centers for Disease Control and Prevention, Pordell, Paran; US Centers for Disease Control and Prevention, Cooney, Caroline; Office of the US Global AIDS Coordinator, Zaidi, Irum; Office of the US Global AIDS Coordinator, Toledo, Carlos; US Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Primary Subject Heading</td>
<td>HIV/AIDS</td>
</tr>
<tr>
<td>Secondary Subject Heading</td>
<td>Global health, Infectious diseases, Sexual health, Urology</td>
</tr>
<tr>
<td>Keywords</td>
<td>Public health &lt; INFECTIOUS DISEASES, HIV &amp; AIDS &lt; INFECTIOUS DISEASES, PREVENTIVE MEDICINE</td>
</tr>
</tbody>
</table>
Progress in Voluntary Medical Male Circumcision for HIV Prevention
Supported by the United States President’s Emergency Plan for AIDS Relief through 2017:
Longitudinal and Recent Cross-sectional Program Data

Stephanie M. Davis¹, Jonas Z. Hines¹, Melissa Habel¹, Jonathan M. Grund¹, Renee Ridzon², Brittney Baack³, Jonathan Davitte⁴, Anne Thomas⁴, Valerian Kiggundu⁵, Naomi Bock¹, Paran Pordell³, Caroline Cooney², Irum Zaidi², Carlos Toledo¹

1: US Centers for Disease Control and Prevention, Division of Global HIV and TB, HIV Prevention Branch, Voluntary Medical Male Circumcision Team, Atlanta, GA
2: Office of the U.S. Global AIDS Coordinator and Health Diplomacy, President’s Emergency Plan for AIDS Relief, Washington, DC
3: US Centers for Disease Control and Prevention, Division of Global HIV and TB, Monitoring, Evaluation, and Data Analytics Branch, Clinical Monitoring and Evaluation Team, Atlanta, Georgia
4: Naval Health Research Center, US Department of Defense HIV/AIDS Prevention Program (DHAPP), San Diego, CA
5: United States Agency for International Development, Washington, DC

Corresponding author:

Stephanie M. Davis, MD, MPH
vic6@cdc.gov

Word Count: 3938
ABSTRACT:

OBJECTIVE This article provides an overview and interpretation of the performance of PEPFAR’s male circumcision program, which has supported the majority of voluntary medical male circumcisions performed for HIV prevention, from its 2007 inception through 2017, and client characteristics in 2017.

DESIGN Longitudinal collection of routine program data and disaggregations.

SETTING 14 countries in sub-Saharan Africa with low baseline male circumcision coverage, high HIV prevalence, and PEPFAR-supported voluntary medical male circumcision programs.

PARTICIPANTS Clients of PEPFAR-supported voluntary medical male circumcision programs directed at males aged 10 years and above.

MAIN OUTCOME MEASURES Numbers of circumcisions performed and disaggregations by age band, result of HIV test offer, procedure technique, and follow-up visit attendance.

RESULTS PEPFAR supported a total of 15,269,720 circumcisions in 14 countries in southern and eastern Africa. In 2017, 45% of clients were under 15 years of age, 8% had unknown HIV status, 1% of those tested were HIV+, and 84% returned for a follow-up visit within 14 days of circumcision.

CONCLUSIONS Over 15 million VMMCs have been supported by PEPFAR since 2007. VMMC continues to attract primarily young clients. The nontrivial proportion of clients not testing for HIV is expected, and may be reassuring that testing is not being presented as mandatory for access to circumcision, or in some cases reflect test kit stockouts or recent testing elsewhere. While VMMC is extremely safe, achieving the highest possible follow-up rates for early diagnosis and intervention on complications is crucial, and programs continue to work to raise follow-up rates. The VMMC program has achieved rapid scale-up but continues to face challenges, and new approaches may be needed to achieve the new UNAIDS goal of 27 million additional circumcisions through 2020.
STRENGTHS AND LIMITATIONS OF THIS STUDY:

- The large dataset covers eleven years of program data on over 15 million men.
- PEPFAR-supported clients constitute a large majority of all voluntary medical male circumcision clients, making client characteristics reported here likely to be representative of the program as a whole.
- The multicountry nature of the data allows determination of client characteristics common across settings.
- The routine reporting system is aggregate only, and collected data does not support analyses of associations between client characteristics.
- Data are not complete for all client characteristics (disaggregations) in all countries.
INTRODUCTION:

Male circumcision, the removal of the foreskin, reduces a man’s risk of acquiring HIV through heterosexual exposure by approximately 60 percent.\textsuperscript{1,2,3} Since its adoption as a recommended HIV prevention strategy by the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) in 2007,\textsuperscript{4} voluntary medical male circumcision (VMMC) has become a core component of the global HIV prevention portfolio through support by national and global programs, such as the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.\textsuperscript{5} The WHO/UNAIDS’s guiding document for VMMC from 2012-2016 recommended scale-up of VMMC in 14 countries in southern and eastern Africa with high HIV prevalence, low circumcision coverage and primarily heterosexual HIV transmission,\textsuperscript{6} with an initial goal of circumcising 20 million men to achieve 80% coverage among males aged 15-49 years in these countries by 2016. As a one-time biomedical intervention conferring lifelong partial protection from HIV, and the only prevention method specifically targeted at HIV-negative heterosexual men, VMMC complements other behavioral and clinical prevention interventions such as condom promotion, reduction in number of sex partners, pre-exposure prophylaxis, and treatment-as-prevention.

VMMC services were launched progressively by ministries of health in each of the recommended 14 countries between 2007 and 2011, primarily with PEPFAR support. PEPFAR-supported VMMCs are surgical or procedural interventions often lasting 5-15 minutes,\textsuperscript{7} provided by physicians or nurses under local anesthesia. They are offered with the WHO-recommended minimum package\textsuperscript{8} of accompanying services, including the offer of HIV testing and linkage to care and treatment for HIV-positive individuals, HIV risk-reduction education, condom provision, and sexually transmitted infection (STI) screening and treatment or referral. Over the lifetime of the program, several additional key innovations with potential to impact the volume and client demographics of the program have also been incorporated. These include the introduction of WHO-prequalified circumcision devices as
alternatives to conventional surgery; the introduction of WHO “Models for Optimizing Volume and Efficiency”;\textsuperscript{9} the identification of the 15-29 year age group as the focal demographic for rapidly reducing population-level HIV incidence through VMMC;\textsuperscript{10} enhancement of safety measures based on accumulating data, particularly for adolescents based on their unique surgical safety requirements; introduction of policies on tetanus vaccination prior to VMMC;\textsuperscript{11} and increased emphasis on linking clients testing HIV-positive to care and treatment,\textsuperscript{12} to support WHO/UNAIDS treatment scale-up goals.\textsuperscript{13}

All PEPFAR-supported VMMC programs report on key program outcomes, including the total VMMCs performed in each country and select disaggregations for all clients: client age range, result of HIV test offer, circumcision technique (device or surgical), and adherence to routine post-operative follow-up. These indicators provide an overview of the accomplishments and key current attributes of the PEPFAR VMMC program. This article presents all PEPFAR-supported VMMCs performed since program inception in 2007, compares key disaggregations from U.S. fiscal year 2017 with those from 2015 and 2016, and discusses future challenges and directions for the program. The primary objective of this paper is to describe PEPFAR’s VMMC program, and identify in which aspects the program is performing well and in which gaps and challenges remain and should be prioritized. Making key demographic data on VMMC clients available may also support refining projections around impact.

Client characteristics described here are expected to be reasonably representative of the global VMMC clientele to date because PEPFAR supports the majority of VMMCs conducted globally (approximately 82% through 2016)\textsuperscript{14}, and because VMMC donors operate under the common WHO minimum package service structure.

**METHODS:**

Data reported by PEPFAR-supported VMMC programs are drawn initially from site-level client registers and records, and reported by the implementing partners at the site level to PEPFAR in each
host country. Data are then cleaned in-country; and then reported to PEPFAR’s central coordinating body, the Office of the Global AIDS Coordinator. Implementing partners also report to their host country governments, following procedures agreed upon in-country; this may occur independently or may use the same data stream. Data are currently reported to PEPFAR on a quarterly basis, and then grouped by U.S. Government fiscal year, which runs October 1st through September 30th, rather than by calendar year. These numerical data are now available online and were used here to calculate percentages where relevant. Monitoring trends across years is possible, but prior to 2015, fewer VMMC disaggregations were collected.

The disaggregations reported for VMMCs performed, and definitions where needed, are listed in table 1. Their rationales and context are summarized below. Not all sites are able to collect and report circumcision data by each disaggregate for all clients. Therefore, percentages presented here for each disaggregate are calculated only among clients for whom data on that disaggregate were reported.
Table 1: Disaggregations and Categories for PEPFAR-supported VMMC program reporting on VMMCs performed, 2016

<table>
<thead>
<tr>
<th>Disaggregation</th>
<th>Client Categories</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>&lt; 61 days (early infant male circumcision)</td>
</tr>
<tr>
<td></td>
<td>2 months-&lt;10 years (not funded by PEPFAR due to safety concerns)</td>
</tr>
<tr>
<td></td>
<td>10-14 years (this and younger categories are collapsed here as '&lt;15')</td>
</tr>
<tr>
<td></td>
<td>15-19 years</td>
</tr>
<tr>
<td></td>
<td>20-24 years</td>
</tr>
<tr>
<td></td>
<td>25-29 years</td>
</tr>
<tr>
<td></td>
<td>30-49 years</td>
</tr>
<tr>
<td></td>
<td>50+ years</td>
</tr>
<tr>
<td><strong>Result of HIV test offer at VMMC site</strong></td>
<td>HIV+</td>
</tr>
<tr>
<td></td>
<td>HIV -</td>
</tr>
<tr>
<td></td>
<td>Unknown: includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason</td>
</tr>
<tr>
<td><strong>Technique</strong></td>
<td>Surgical</td>
</tr>
<tr>
<td></td>
<td>Device-based</td>
</tr>
<tr>
<td><strong>Follow-up visit attendance</strong></td>
<td>Returned for at least one post-operative follow-up visit within 14 days of surgery</td>
</tr>
<tr>
<td></td>
<td>Did not return within 14 days</td>
</tr>
</tbody>
</table>

1) **Client age range**: Age ranges represent those selected for PEPFAR routine reporting to support fine analysis of client age patterns. PEPFAR’s prioritization of, or “age pivot” to, the 15-29 year age range began in fiscal year 2016. Ages below 15 years constitute the largest combined proportion of VMMCs performed, but will have delayed impact on the HIV epidemic due to the delay until sexual debut and other risk behaviors. These age ranges are collapsed together in this report.

2) **Result of HIV test offer at VMMC site**: Under PEPFAR\(^1\), UNAIDS\(^2\) and WHO\(^3\) guidance active in 2016, HIV testing at the VMMC site should be encouraged but is not required for access to VMMC, and clinically eligible clients who do test may proceed with VMMC regardless of their results. As a disaggregation within the cohort of clients receiving VMMC, this reporting does not include men who were tested at VMMC sites but then decided against VMMC after receiving a positive HIV test result. This may not be unusual, as men testing...
positive are counseled that circumcision will not affect the course of their HIV infection and may choose not to proceed.

3) **Circumcision technique used:** Circumcision devices offer an alternative to surgery, and advantages include faster procedures and potentially avoiding the injection of anesthesia and incision of living tissue. Initially, PEPFAR-supported circumcision was exclusively surgical, using one of three WHO-recommended techniques: forceps-guided, dorsal slit, and sleeve resection.\(^{19}\) With WHO prequalification of the PrePex device in 2013\(^ {20}\) and ShangRing in 2015,\(^ {21}\) some ministries of health have introduced device-based services as additional options for clients. Both PrePex and ShangRing devices remain on the penis for seven days and are removed by a provider during a follow-up visit. Anatomic and age-based eligibility criteria vary between devices and can be stricter than surgical eligibility criteria, restricting the pool of eligible clients.\(^ {22}\) Numbers of circumcisions performed using a device therefore reflect national policies and eligibility for, as well as availability and client uptake of, these alternative methods. They also reflect the impact of tetanus mitigation policies as discussed below.

4) **Follow-up visit attendance:** PEPFAR-supported programs follow fixed schedules for routine postoperative follow-up set by national ministries of health to ensure client safety. These often include a return visit at days two and seven after surgery, or day seven after device placement (for device removal). In 2015 and 2016, the PEPFAR follow-up indicator was only reported among surgical cases, which therefore constituted the denominator for determining follow-up percentage; in 2017 it was calculated among all circumcisions. Followup was only reported on if it took place, so that clients who did not follow up cannot be distinguished from those whose followup status is unknown.
Comparison data on country-specific total annual VMMC volume (including both PEPFAR-supported and non-PEPFAR supported procedures) is drawn from the most recent WHO VMMC Progress Brief, covering 2007-2016. Data on PEPFAR’s 2017 country-level VMMC targets is drawn from annual PEPFAR Budget and Target reports.

Patient and public involvement: Because this manuscript reports program data rather than research data, no research question or study design was formulated for data collection. Data collected instead consists of indicators designed to monitor program achievements. VMMC clients were beneficiaries choosing to uptake a public health interventions, not research participants. However, satisfied VMMC clients are sometimes involved in recruiting peers for VMMC. Results are publically available online as referenced above.

RESULTS:

From PEPFAR fiscal year 2007 through 2017, a total of 15,269,720 PEPFAR-supported VMMCs were performed in 14 countries in southern and eastern Africa. From 2010 through 2014, annual VMMC numbers approximately doubled annually, reaching 2,794,808 in 2014. In 2015, 2,573,273 VMMCs were performed, followed in 2016 by 2,290,200; these represented the third- and fourth-highest annual totals. The year 2017 saw an increase to 3,665,866, the highest annual total to date. Over half (54%) of PEPFAR-supported circumcisions performed since the program’s inception were performed in 2015-2017 (Figure 1, Table 2). In 2016, the latest year for which WHO national-level data is available, PEPFAR-supported VMMCs constituted 80% of all VMMCs reported by WHO, and 55% or more of reported VMMCs in each individual country except Rwanda. VMMCs conducted in 2017 achieved 92% (3,664,531/3,665,866) of PEPFAR targets for that year, with nine countries reaching 90% or more of their targets.
Twelve countries provided >85% data completeness across all disaggregations in 2017 for which completeness was calculable. By disaggregate, 3,278,130 clients had age data (387,736 missing = 12%); 3,309,077 had result of HIV test offer (including unknown status; 356,789 missing = 11%); 3,282,987 had technique data (382,879 missing = 12%); of whom 2,736,851 had a reported follow-up within 14 days. Because programs only reported the number of clients who received follow-up in 2017, and did not separately report the number which did not, we are unable to assess completeness for this disaggregate (but see table 2 footnote). Where data completeness for a given disaggregate in a country (sum of all VMMCs across categories for that disaggregate, divided by total VMMCs performed) was less than the 85% threshold we selected for this analysis, values are bolded (Table 3).

In 2017, 48% of VMMC clients were within the 15-29 years age range, to which PEPFAR shifted focus that year, a relatively stable proportion from 46% in 2016 and 48% in 2015. There was wide variation among countries, ranging from 25% in Botswana to 68% in Rwanda. In contrast, 45% of PEPFAR VMMC clients were within the 10-14 years range, representing a stable increase, along with 46% in 2016, from 42% in 2015. Eight countries experienced an increase in the proportion of clients in the 10-14 year age range from 2016 to 2017. This shift was largest in Rwanda (5% to 28%), Botswana (45% to 66%), and Namibia (12% to 34%), all relatively small programs. However other programs, like South Africa, did successfully achieve the reverse (43% in 2017, from 51% in 2016). Countries which had previously shifted in 2016 toward younger clientele included several large programs which also showed decreases in overall achievements in that year, such as Tanzania, South Africa and Zambia, though in the first two cases this trend reversed in 2017.
PEPFAR circumcisions through 2017

Table 2: Annual PEPFAR-funded VMMCs performed by country, 2007-2017, and PEPFAR 2017 VMMC targets*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>5,180</td>
<td>534</td>
<td>0</td>
<td>8,590</td>
<td>12,464</td>
<td>13,893</td>
<td>7,712</td>
<td>24,201</td>
<td>22,645</td>
<td>20,911</td>
<td>95,219</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>0</td>
<td>3,110</td>
<td>8,236</td>
<td>12,445</td>
<td>16,393</td>
<td>11,831</td>
<td>11,307</td>
<td>14,335</td>
<td>13,782</td>
<td>17,184</td>
<td>91,439</td>
</tr>
<tr>
<td>Kenya</td>
<td>45,657</td>
<td>112,574</td>
<td>182,788</td>
<td>214,851</td>
<td>229,390</td>
<td>233,813</td>
<td>264,490</td>
<td>227,272</td>
<td>240,010</td>
<td>1,669,113</td>
<td></td>
</tr>
<tr>
<td>Lesotho</td>
<td>0</td>
<td>0</td>
<td>199</td>
<td>6,971</td>
<td>36,418</td>
<td>39,175</td>
<td>28,909</td>
<td>31,709</td>
<td>25,445</td>
<td>40,573</td>
<td>168,826</td>
</tr>
<tr>
<td>Malawi</td>
<td>0</td>
<td>0</td>
<td>778</td>
<td>13,314</td>
<td>67,384</td>
<td>68,334</td>
<td>90,820</td>
<td>82,381</td>
<td>99,435</td>
<td>109,348</td>
<td>422,446</td>
</tr>
<tr>
<td>Mozambique</td>
<td>0</td>
<td>4,009</td>
<td>18,946</td>
<td>79,002</td>
<td>129,581</td>
<td>160,660</td>
<td>187,186</td>
<td>241,793</td>
<td>315,239</td>
<td>427,536</td>
<td>1,136,416</td>
</tr>
<tr>
<td>Namibia</td>
<td>117</td>
<td>1,229</td>
<td>5,379</td>
<td>6,121</td>
<td>0**</td>
<td>785</td>
<td>9,927</td>
<td>15,116</td>
<td>27,736</td>
<td>34,746</td>
<td>66,410</td>
</tr>
<tr>
<td>Rwanda</td>
<td>0</td>
<td>896</td>
<td>3,922</td>
<td>17,639</td>
<td>36,441</td>
<td>74,803</td>
<td>65,048</td>
<td>50,204</td>
<td>175,902</td>
<td>95,936</td>
<td>424,855</td>
</tr>
<tr>
<td>South Africa</td>
<td>18,100</td>
<td>14,956</td>
<td>72,004</td>
<td>170,849</td>
<td>294,977</td>
<td>327,473</td>
<td>472,047</td>
<td>355,917</td>
<td>460,668</td>
<td>428,486</td>
<td>2,186,991</td>
</tr>
<tr>
<td>Swaziland</td>
<td>3,802</td>
<td>19,728</td>
<td>13,399</td>
<td>14,456</td>
<td>9,708</td>
<td>11,934</td>
<td>12,156</td>
<td>16,003</td>
<td>15,071</td>
<td>18,616</td>
<td>116,257</td>
</tr>
<tr>
<td>Tanzania</td>
<td>262</td>
<td>21,581</td>
<td>117,351</td>
<td>151,915</td>
<td>381,394</td>
<td>554,673</td>
<td>615,089</td>
<td>519,437</td>
<td>696,572</td>
<td>696,449</td>
<td>3,058,274</td>
</tr>
<tr>
<td>Uganda</td>
<td>0</td>
<td>9,052</td>
<td>57,132</td>
<td>352,039</td>
<td>742,978</td>
<td>906,615</td>
<td>466,650</td>
<td>330,343</td>
<td>753,198</td>
<td>1,011,964</td>
<td>3,618,007</td>
</tr>
<tr>
<td>Zambia</td>
<td>0</td>
<td>21,236</td>
<td>63,444</td>
<td>103,517</td>
<td>199,372</td>
<td>239,464</td>
<td>216,394</td>
<td>185,028</td>
<td>323,180</td>
<td>271,260</td>
<td>1,351,635</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>0</td>
<td>9,811</td>
<td>30,608</td>
<td>36,765</td>
<td>88,114</td>
<td>155,778</td>
<td>156,215</td>
<td>159,243</td>
<td>227,299</td>
<td>252,847</td>
<td>863,833</td>
</tr>
<tr>
<td>Total</td>
<td>73,118</td>
<td>218,716</td>
<td>574,186</td>
<td>1,131,900</td>
<td>2,230,075</td>
<td>2,794,808</td>
<td>2,573,273</td>
<td>2,290,200</td>
<td>3,383,444</td>
<td>3,665,866</td>
<td>15,269,720</td>
</tr>
</tbody>
</table>
PEPFAR circumcisions through 2017

* Fiscal years
** PEPFAR support for VMMC in Namibia was paused for strategic planning in 2013.
PEPFAR circumcisions through 2017

Table 3: Numbers and Characteristics of PEPFAR-funded Voluntary Medical Male Circumcisions, Fiscal Year 2017 (Oct. 1, 2016-Sept 30, 2017) by country and 2015-2016 totals

<table>
<thead>
<tr>
<th>Country</th>
<th>VMMCs</th>
<th>Client Age Range in Years (%)*</th>
<th>Result of HIV test offer at VMMC site (%)</th>
<th>Technique: Device Method Used (%) (vs. Surgical)</th>
<th>Follow-up Visit Attendance **(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;15</td>
<td>15-19</td>
<td>20-24</td>
<td>25-29</td>
</tr>
<tr>
<td>Botswana</td>
<td>22,645</td>
<td>66</td>
<td>10</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>13,782</td>
<td>47</td>
<td>26</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>Kenya</td>
<td>227,272</td>
<td>60</td>
<td>23</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Lesotho</td>
<td>25,445</td>
<td>56</td>
<td>18</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Malawi</td>
<td>99,435</td>
<td>42</td>
<td>28</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Mozambique</td>
<td>315,239</td>
<td>45</td>
<td>30</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Namibia</td>
<td>27,736</td>
<td>34</td>
<td>21</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>Rwanda</td>
<td>175,902</td>
<td>28</td>
<td>48</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>South Africa</td>
<td>460,668</td>
<td>43</td>
<td>22</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>Swaziland</td>
<td>15,071</td>
<td>54</td>
<td>29</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Tanzania</td>
<td>696,572</td>
<td>46</td>
<td>26</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>Uganda</td>
<td>753,198</td>
<td>46</td>
<td>26</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Zambia</td>
<td>323,180</td>
<td>38</td>
<td>27</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>227,299</td>
<td>47</td>
<td>25</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Total in 2017</td>
<td>3,383,444</td>
<td>45</td>
<td>27</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Total in 2016</td>
<td>2,290,141</td>
<td>46</td>
<td>27</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>Total in 2015</td>
<td>2,573,238</td>
<td>42</td>
<td>28</td>
<td>13</td>
<td>7</td>
</tr>
</tbody>
</table>

**Bolded** entries indicate <85% data completeness.

* Includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason

** Percent of clients who returned for at least one post-operative follow-up visit within 14 days of surgery or device placement

*** Follow-up rate in Zimbabwe unknown for 2017. Facilities representing 46% of all Zimbabwe circumcisions did not report followup data, due to delays in adoption of the new follow-up reporting method.
PEPFAR circumcisions through 2017

Overall, 8% of clients had “unknown” HIV status in 2017, as compared to 9% in 2016 and 7% in 2015, with individual country values ranging from 0% in Rwanda and Zimbabwe to 50% in Lesotho; other countries with high “unknown” rates were Ethiopia at 32% and Namibia at 44%. Among clients tested for HIV, 1% were positive, essentially unchanged from 2015-2016, with individual country positivity varying between 0% in Zimbabwe, Tanzania, Mozambique and Ethiopia, and 5% in Malawi.

Device-based circumcision techniques constituted a small percentage of circumcisions in all countries in 2017, accounting for 3% of VMMCs across countries (down from 5% in 2015 and 4% in 2016), ranging between 0% in many countries and 53% in Rwanda. Botswana and Zimbabwe showed substantial respective drops from 28% to 0% and 27% to 5%.

Post-procedure follow-up rates among all clients were 84% overall (excluding Zimbabwe), higher than the 72% in 2015 and 78% in 2016. These rates ranged between 59% in South Africa and 100% in Rwanda, falling at or above 75% in 11 countries.

DISCUSSION:

VMMC has undergone a scale-up of historic proportions within global health, comparable to the scale-up of HIV treatment. This manuscript demonstrates that overall program volume is high and increasing, but there is progress to be made in increasing volume further to pursue Fast Track targets, attracting older clients with higher HIV risk and, in some places, raising postoperative follow-up rates to ensure complications are managed promptly.
PEPFAR circumcisions through 2017

With respect to program volume, over 15 million PEPFAR-supported VMMCs were performed between 2007 when support began and 2017, making VMMC a major prevention intervention for achieving the PEPFAR goal of an AIDS-free generation through epidemic control in sub-Saharan Africa. PEPFAR had committed in 2015 to supporting at least 13 million VMMCs through 2017, and exceeded that target. Models estimate that global VMMCs conducted through 2016 alone will avert 500,000 infections by the end of 2030. Scale-up has been enabled not only by dedicated resources, totaling over $1.5 billion through 2017 from PEPFAR alone, but also through leadership from ministries of health, rapid expansion of surgical skills and responsibilities to non-physician health cadres, and public outreach campaigns. It has provided millions of men with lifelong partial protection from HIV and some STIs, and connected them with additional HIV and other health services through testing, STI screening, and referrals for other health conditions. Infections averted in men through VMMC also help prevent new HIV infections among women and girls, and male circumcision is also associated with lower prevalence of a range of STIs in women.

In light of the high proportion of global VMMCs supported, PEPFAR client data is also expected to provide a reasonably representative view of the global VMMC clientele to date. References to achievements and characteristics below refer to the PEPFAR program except where otherwise stated.

All VMMC implementing countries continue to scale up VMMC. However, in 2015 and 2016 there were substantial declines in PEPFAR VMMC achievements in Uganda (the largest contributor to VMMC results); these were mirrored by declines in total VMMCs achieved in Uganda. Service delivery and policy were impacted by the identification of tetanus as a risk among VMMC clients in the Ugandan setting, due to limited historical tetanus immunization coverage. WHO issued global recommendations that additional visits for tetanus vaccination be performed prior to circumcision using...
PEPFAR circumcisions through 2017

device-based VMMC methods associated with increased risk of tetanus,\textsuperscript{33} and the Uganda National VMMC Program ultimately required an additional visit for tetanus vaccination prior to VMMC. Similar policies may have also impacted performance in other countries with significant device contributions (not shown) like Botswana and Rwanda. Additionally, a PEPFAR policy issued in late 2014 discontinued the use of the forceps-guided surgical technique in young adolescents to avoid the associated risk for injury to the immature glans, causing some country programs to decrease VMMC provision to this age range until they could retrain their VMMC workforces in a more appropriate method. In 2016, Tanzania, South Africa and Zambia also experienced declines (Uganda had not previously reported age data), though these were accompanied by increases in client proportions in the 10-14 age group, and were followed in 2017 by increases in overall performance and shifts toward older clientele. These 2016 declines may thus be due to strategic shifts in program geography and funding. Total program performance then increased substantially in 2017, with nine countries showing increases over 2016, including these largest programs. We attribute this recovery to resolution of the challenges described above, combined with increases in available resources.

Country-level PEPFAR VMMC targets are set each year for the following year, based on previous years’ achievements, available resources, overall ministry of health targets, and remaining unmet need to achieve saturation. In 2017, overall performance was well-matched to targets (92%), with variations including some countries with marked overperformance (Rwanda and Zambia) and others with high absolute performance but even more ambitious targets (e.g. Uganda, with the highest national PEPFAR VMMC performance ever reported). In addition to the policy factors discussed above, reasons for variation in performance against targets can include implementing partner capacity and
PEPFAR circumcisions through 2017

ambition (partners may choose to surpass their targets once achieved, if funding remains) and unexpected external factors such as civil unrest and health care strikes.

VMMC client populations in 2017 were young, with males in the 10-14 years age range representing 45% of all PEPFAR VMMCs (virtually all VMMCs in clients <15 years are in the 10-14 year range), as compared to 12% of the combined male general population of the 14 implementing countries. This represents a change from the program’s historical client age distribution; from 2010 through 2013, clients in the 10-14 years age range characterized no more than one third of all clients in any year. The 2015 distribution (42% of clients were aged <15 years) served as the baseline prior to implementation of the “age pivot”; yet the actual age balance shifted further toward the younger range in 2016 (46%), with only slight recovery in 2017, despite this focus. In some countries, the shift toward younger ages may partially reflect the maturation of the VMMC program: ‘exhaustion’ of older age ranges and replacement with younger males. Additional potential barriers which may apply disproportionately to older males include reluctance to abstain from sex for the 6-week healing period, perception of low risk due to having established partners, the opportunity cost of lost wages during recovery, and fear of creating perceptions in a stable partner that they intend to seek other sexual partners. Age ranges 30 years and above represented a small (8% in 2017) percentage of VMMC clientele, despite being a sexually active group at risk for HIV, possibly for similar reasons. However, some countries and individual partners did successfully make modest shifts toward older clientele, and identification and broader adoption of their best practices are called for.

VMMC clients also have low HIV positivity compared to the general population, 1% among all clients in 2015, 2016 and 2017, as compared to 5.5% (95% confidence interval 4.9-6.0%) prevalence among males aged 15-49 years in the southern and eastern Africa region in 2016. The young age of
PEPFAR circumcisions through 2017

the client population is almost certainly the major underlying factor; pre-adolescents and early
adolescents have less exposure to sex and consequently less HIV risk and lower HIV prevalence than
older age groups. Because HIV test results are not disaggregated by age group, this effect cannot be
controlled for in PEPFAR VMMC reporting data. Lower HIV prevalence among VMMC clients could
also reflect self-selection of men with health-protecting behaviors into the pool of VMMC clients and/or
the effects of messaging promoting VMMC for HIV prevention, leading to the self-exclusion of men
who know they are HIV-positive (including any who learn they are HIV-positive at the VMMC site and
consequently opt out of VMMC). Despite this low prevalence, it should be noted that men in sub-
Saharan Africa have lower HIV testing uptake than women\textsuperscript{39} and the VMMC program provides an
opportunity to reach men who might not otherwise undergo testing. The substantial proportion of clients
with ‘unknown’ test results is expected, and may reflect the voluntary nature of HIV testing in VMMC,
as well as the frequency of HIV test kit stockouts (e.g., Ethiopia and Namibia experienced intermittent
stockouts in 2017).

The fact that few circumcisions were performed by device methods throughout 2015-2017
reflects in part the relatively short period that device-based circumcision has been available, as well as
the rigorous country-level vetting process which new devices undergo when being introduced in a new
country,\textsuperscript{40} prior to nationwide rollout. It may also reflect current preferences of clients and programs.
As of publication, all countries implementing PEPFAR-supported VMMC except Ethiopia and Namibia
have begun the evaluation process for at least one device, although scale-up of device-based service
delivery can take time even after evaluation is completed and policy is in place. Although devices offer
several advantages over surgical circumcision, they require more intense post-market safety monitoring
tailored to their mechanisms of action, until more VMMCs have been done using these methods. Most
PEPFAR circumcisions through 2017

recently, uptake of the most commonly-used device has also been negatively impacted by the WHO advice and PEPFAR policy related to tetanus vaccination prior to device placement,\textsuperscript{41} driving the decline noted from 2015-2017.

Although the follow-up rate of 84\% in 2017 is not precisely comparable to rates in 2015 and 2016 because of the inclusion of device followup, the low proportion of the program represented by device MCs makes the apparent increase likely to constitute a true trend. Followup is also likely to be underestimated, because all clients without a reported followup visit were treated in calculations as not following up, rather than missing data. This is encouraging, but more remains to be done in countries with low follow-up rates. There is evidence that adverse events (AEs) are actually more common among males who do not return for follow-up than among those who do.\textsuperscript{42} While VMMC is extremely safe,\textsuperscript{43} achieving high follow-up rates to allow early AE diagnosis and intervention is crucial for program safety.

The findings in this paper are subject to several limitations. These data reflect results supported by PEPFAR, rather than country totals. Additionally, cross-tabulations between disaggregations are not reported, and therefore it is not possible to determine associations between age range, result of HIV test offer and procedure technique, or control for measured potential confounders. For reasons discussed above, VMMC clients are not representative of the general male population of their countries; they are younger, less likely to be HIV-positive, and possibly at lower behavioral risk; findings here are not intended to be generalized outside the client population. Data entry errors such as those discussed above for follow-up, and variations in reporting practice, are possible. Category definitions combine some disparate groups (e.g. “unknown” test results include men who were not tested at VMMC sites for any reason, whether preference, test kit shortage, or documentation of recent outside testing.) Finally, though
PEPFAR circumcisions through 2017

we believe client characteristics are representative of those of all VMMC clients, PEPFAR’s focus on the areas of each country with highest absolute HIV burden could mean that clients of other VMMC programs in other areas (which may have lower HIV incidence and prevalence, or simply be less densely populated) differ demographically, in unknown ways.

The global VMMC program’s achievements to date have demonstrated the feasibility of rapid scale-up of circumcision coverage, but program strategy will need to continue evolving to maximize impact, achieve revised targets, maintain safety, and meet broader UNAIDS and PEPFAR objectives of integrating services into existing health care systems. Though current achievements have totalled the majority of the initial global target, this target was recently revised under the new UNAIDS Fast Track framework to include 27 million additional circumcisions by the end of 2020 beyond those conducted through 2015, to reach 90% coverage among 10-29-year-olds. Reaching these VMMC targets is a key component of the Fast Track strategy: the overall impact projection for achievement of Fast Track goals – 28 million HIV infections averted by 2030 – depends in part on achieving and maintaining this coverage. Among these, attracting the PEPFAR priority subpopulation of clients in the 15-29 years age range, and ideally other high-risk clients who will benefit most from VMMC, will yield the fastest impact on HIV incidence but may require new demand creation approaches and service delivery models. Finally, the updated 2016 WHO/UNAIDS framework for VMMC calls for circumcision programs to shift from largely stand-alone service delivery toward greater integration within a broad platform of adolescent and adult male reproductive health. Strategies that reached “early adopters” predisposed to uptake VMMC rapidly may differ from those needed to reach the remaining uncircumcised men, and to do so within this integrated platform. To achieve the ambitious goals in this framework, substantial
PEPFAR circumcisions through 2017

engagement and increased resource commitments from stakeholders other than PEPFAR, including national ministries of health, will be needed.

**FUNDING:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sections. It was supported in part by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).

**COMPETING INTERESTS:** Authors declare no competing interests.

**DISCLAIMER:** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies, the Centers for Disease Control and Prevention, the US Agency for International Development, or the United States Government.

**CONTRIBUTORSHIP:** Stephanie M. Davis drafted and finalized the manuscript.

Jonas Hines, Melissa Habel, Jonathan M. Grund, Renee Ridzon, Jonathan Davitte, Anne Thomas, Valerian Kiggundu, Caroline Cooney, and Naomi Bock revised the manuscript.

Brittney Baack and Paran Pordell revised the data and manuscript.

Carlos Toledo conceived of the paper, obtained the data, and revised the manuscript.

Irum Zaidi oversaw all data collection.

**DATA SHARING:** As described in this article, the dataset underlying the tables and results is publically available at [https://data.pepfar.net/quarterlyData/](https://data.pepfar.net/quarterlyData/).
PEPFAR circumcisions through 2017

ETHICAL STATEMENT: Use of this routinely collected, aggregate-only program data was reviewed and approved by CDC Human Subjects Protection.

RESEARCH REPORTING CHECKLISTS: Because this manuscript is based on routinely collected program data and does not examine associations between risk factors and outcomes, none of the standard checklists are entirely applicable, including per EquatorWizard. At the editors’ request, the STROBE checklist has been filled and included with resubmission.
PEPFAR circumcisions through 2017

Figure Legend

**Figure 1:** Cumulative Number of PEPFAR-supported Voluntary Medical Male Circumcisions by Country, 2007-2017
REFERENCES


PEPFAR circumcisions through 2017


PEPFAR circumcisions through 2017


30 Uganda Ministry of Health. Memo Re: The need for tetanus vaccination for men undergoing circumcision and the continued scale-up of safe male circumcision using PrePex.” December 30, 2015.


PEPFAR circumcisions through 2017


Figure 1: Cumulative Number of PEPFAR-supported Voluntary Medical Male Circumcisions by Country, fiscal years 2007-2017

152x95mm (300 x 300 DPI)
<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title and abstract</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 1 | *(a)* Indicate the study’s design with a commonly used term in the title or the abstract – pg 1 (page numbers are for clean version)  
*(b)* Provide in the abstract an informative and balanced summary of what was done and what was found – pg 2 |
| **Introduction** |  
| 2 | Explain the scientific background and rationale for the investigation being reported – pg 4-6 |
| **Objectives** |  
| 3 | State specific objectives, including any prespecified hypotheses – pg 5 |
| **Methods** |  
| 4 | Present key elements of study design early in the paper – pg 5 |
| 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – pp 4-6 |
| 6 | *(a)* Give the eligibility criteria, and the sources and methods of selection of participants – pg 5 |
| **Variables** |  
| 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable – pg 7 |
| 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group – pg 7 |
| **Bias** |  
| 9 | Describe any efforts to address potential sources of bias – pg 18 (this is a limitation of the way program data is collected) |
| **Study size** |  
| 10 | Explain how the study size was arrived at – pg 5 (all clients – program data) |
| **Quantitative variables** |  
| 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why – pg 7-10 |
| **Statistical methods** |  
| 12 | *(a)* Describe all statistical methods, including those used to control for confounding – pg 6-8, 18  
*(b)* Describe any methods used to examine subgroups and interactions - N/A (no subgroups, no interactions)  
*(c)* Explain how missing data were addressed – pg 6, 10  
*(d)* If applicable, describe analytical methods taking account of sampling strategy (N/A)  
*(e)* Describe any sensitivity analyses (N/A) |
| **Results** |  
| 13* | *(a)* Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed - pg 10 provides total numbers, but there are no exclusion stages for program data like those described above  
*(b)* Give reasons for non-participation at each stage - N/A  
*(c)* Consider use of a flow diagram - N/A |
| **Descriptive data** |  
| 14* | *(a)* Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders – pg 12  
*(b)* Indicate number of participants with missing data for each variable of interest – pg 11 |
| **Outcome data** |  
| 15* | Report numbers of outcome events or summary measures – pg 12 |
Main results 16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included – pg 12 (confidence intervals are not applicable because the data represents a census of the client population rather than a sample, and is not being extrapolated to any larger population), 17

(b) Report category boundaries when continuous variables were categorized – pg 7

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period – N/A

Other analyses 17

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses – N/A

Discussion

Key results 18

Summarise key results with reference to study objectives – pp13-18

Limitations 19

Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – pp 18-19

Interpretation 20

Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – pp 13-18

Generalisability 21

Discuss the generalisability (external validity) of the study results – pg 19

Other information

Funding 22

Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – pg 20

*Give information separately for exposed and unexposed groups.

Progress in Voluntary Medical Male Circumcision for HIV Prevention
Supported by the United States President’s Emergency Plan for AIDS Relief through 2017:
Longitudinal and Recent Cross-sectional Program Data

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2018-021835.R2</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Research</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>26-Jul-2018</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Davis, Stephanie; US Centers for Disease Control and Prevention, Hines, Jonas; US Centers for Disease Control and Prevention, Habel, Melissa; US Centers for Disease Control and Prevention, Grund, Jonathan; US Centers for Disease Control and Prevention, Ridzon, Renee; Office of the US Global AIDS Coordinator, Baack, Brittney; US Centers for Disease Control and Prevention, Davitte, Jonathan; US Department of Defense, Naval Health Research Center, Thomas, Anne; US Department of Defense, Naval Health Research Center, Kiggundu, Valerian; United States Agency for International Development, Bock, Naomi; US Centers for Disease Control and Prevention, Pordell, Paran; US Centers for Disease Control and Prevention, Cooney, Caroline; Office of the US Global AIDS Coordinator, Zaidi, Irum; Office of the US Global AIDS Coordinator, Toledo, Carlos; US Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Primary Subject Heading:</td>
<td>HIV/AIDS</td>
</tr>
<tr>
<td>Secondary Subject Heading:</td>
<td>Global health, Infectious diseases, Sexual health, Urology</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Public health &lt; INFECTIOUS DISEASES, HIV &amp; AIDS &lt; INFECTIOUS DISEASES, PREVENTIVE MEDICINE</td>
</tr>
</tbody>
</table>
Progress in Voluntary Medical Male Circumcision for HIV Prevention
Supported by the United States President’s Emergency Plan for AIDS Relief through 2017:
Longitudinal and Recent Cross-sectional Program Data

Stephanie M. Davis, Jonas Z. Hines, Melissa Habel, Jonathan M. Grund, Renee Ridzon, Brittney
Baack, Jonathan Davitte, Anne Thomas, Valerian Kiggundu, Naomi Bock, Paran Pordell, Caroline
Cooney, Irum Zaidi, Carlos Toledo

1: US Centers for Disease Control and Prevention, Division of Global HIV and TB, HIV Prevention
Branch, Voluntary Medical Male Circumcision Team, Atlanta, GA
2: Office of the U.S. Global AIDS Coordinator and Health Diplomacy, President’s Emergency Plan for
AIDS Relief, Washington, DC
3: US Centers for Disease Control and Prevention, Division of Global HIV and TB, Monitoring,
Evaluation, and Data Analytics Branch, Clinical Monitoring and Evaluation Team, Atlanta, Georgia
4: Naval Health Research Center, US Department of Defense HIV/AIDS Prevention Program (DHAPP),
San Diego, CA
5: United States Agency for International Development, Washington, DC

Corresponding author:
Stephanie M. Davis, MD, MPH
vic6@cdc.gov

Word Count: 3938
ABSTRACT:

OBJECTIVE This article provides an overview and interpretation of the performance of PEPFAR’s male circumcision program, which has supported the majority of voluntary medical male circumcisions performed for HIV prevention, from its 2007 inception through 2017, and client characteristics in 2017.

DESIGN Longitudinal collection of routine program data and disaggregations.

SETTING 14 countries in sub-Saharan Africa with low baseline male circumcision coverage, high HIV prevalence, and PEPFAR-supported voluntary medical male circumcision programs.

PARTICIPANTS Clients of PEPFAR-supported voluntary medical male circumcision programs directed at males aged 10 years and above.

MAIN OUTCOME MEASURES Numbers of circumcisions performed and disaggregations by age band, result of HIV test offer, procedure technique, and follow-up visit attendance.

RESULTS PEPFAR supported a total of 15,269,720 circumcisions in 14 countries in southern and eastern Africa. In 2017, 45% of clients were under 15 years of age, 8% had unknown HIV status, 1% of those tested were HIV+, and 84% returned for a follow-up visit within 14 days of circumcision.

CONCLUSIONS Over 15 million VMMCs have been supported by PEPFAR since 2007. VMMC continues to attract primarily young clients. The nontrivial proportion of clients not testing for HIV is expected, and may be reassuring that testing is not being presented as mandatory for access to circumcision, or in some cases reflect test kit stockouts or recent testing elsewhere. While VMMC is extremely safe, achieving the highest possible follow-up rates for early diagnosis and intervention on complications is crucial, and programs continue to work to raise follow-up rates. The VMMC program has achieved rapid scale-up but continues to face challenges, and new approaches may be needed to achieve the new UNAIDS goal of 27 million additional circumcisions through 2020.
STRENGTHS AND LIMITATIONS OF THIS STUDY:

- The large dataset covers eleven years of program data on over 15 million men.

- PEPFAR-supported clients constitute a large majority of all voluntary medical male circumcision clients, making client characteristics reported here likely to be representative of the program as a whole.

- The multicountry nature of the data allows determination of client characteristics common across settings.

- The routine reporting system is aggregate only, and collected data does not support analyses of associations between client characteristics.

- Data are not complete for all client characteristics (disaggregations) in all countries.
INTRODUCTION:

Male circumcision, the removal of the foreskin, reduces a man’s risk of acquiring HIV through heterosexual exposure by approximately 60 percent.\textsuperscript{1,2,3} Since its adoption as a recommended HIV prevention strategy by the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) in 2007,\textsuperscript{4} voluntary medical male circumcision (VMMC) has become a core component of the global HIV prevention portfolio through support by national and global programs, such as the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.\textsuperscript{5} The WHO/UNAIDS’s guiding document for VMMC from 2012-2016 recommended scale-up of VMMC in 14 countries in southern and eastern Africa with high HIV prevalence, low circumcision coverage and primarily heterosexual HIV transmission,\textsuperscript{6} with an initial goal of circumcising 20 million men to achieve 80% coverage among males aged 15-49 years in these countries by 2016. As a one-time biomedical intervention conferring lifelong partial protection from HIV, and the only prevention method specifically targeted at HIV-negative heterosexual men, VMMC complements other behavioral and clinical prevention interventions such as condom promotion, reduction in number of sex partners, pre-exposure prophylaxis, and treatment-as-prevention.

VMMC services were launched progressively by ministries of health in each of the recommended 14 countries between 2007 and 2011, primarily with PEPFAR support. PEPFAR-supported VMMCs are surgical or procedural interventions often lasting 5-15 minutes,\textsuperscript{7} provided by physicians or nurses under local anesthesia. They are offered with the WHO-recommended minimum package\textsuperscript{8} of accompanying services, including the offer of HIV testing and linkage to care and treatment for HIV-positive individuals, HIV risk-reduction education, condom provision, and sexually transmitted infection (STI) screening and treatment or referral. Over the lifetime of the program, several additional key innovations with potential to impact the volume and client demographics of the program have also been incorporated. These include the introduction of WHO-prequalified circumcision devices as
alternatives to conventional surgery; the introduction of WHO “Models for Optimizing Volume and Efficiency”; the identification of the 15-29 year age group as the focal demographic for rapidly reducing population-level HIV incidence through VMMC; enhancement of safety measures based on accumulating data, particularly for adolescents based on their unique surgical safety requirements; introduction of policies on tetanus vaccination prior to VMMC; and increased emphasis on linking clients testing HIV-positive to care and treatment, to support WHO/UNAIDS treatment scale-up goals.

All PEPFAR-supported VMMC programs report on key program outcomes, including the total VMMCs performed in each country and select disaggregations for all clients: client age range, result of HIV test offer, circumcision technique (device or surgical), and adherence to routine post-operative follow-up. These indicators provide an overview of the accomplishments and key current attributes of the PEPFAR VMMC program. This article presents all PEPFAR-supported VMMCs performed since program inception in 2007, compares key disaggregations from U.S. fiscal year 2017 with those from 2015 and 2016, and discusses future challenges and directions for the program. The primary objective of this paper is to describe PEPFAR’s VMMC program, and identify in which aspects the program is performing well and in which gaps and challenges remain and should be prioritized. Making key demographic data on VMMC clients available may also support refining projections around impact. Client characteristics described here are expected to be reasonably representative of the global VMMC clientele to date because PEPFAR supports the majority of VMMCs conducted globally (approximately 82% through 2016), and because VMMC donors operate under the common WHO minimum package service structure.

**METHODS:**

Data reported by PEPFAR-supported VMMC programs are drawn initially from site-level client registers and records, and reported by the implementing partners at the site level to PEPFAR in each
host country. Data are then cleaned in-country; and then reported to PEPFAR’s central coordinating body, the Office of the Global AIDS Coordinator. Implementing partners also report to their host country governments, following procedures agreed upon in-country; this may occur independently or may use the same data stream. Data are currently reported to PEPFAR on a quarterly basis, and then grouped by U.S. Government fiscal year, which runs October 1st through September 30th, rather than by calendar year. These numerical data are now available online\textsuperscript{15} and were used here to calculate percentages where relevant. Monitoring trends across years is possible, but prior to 2015, fewer VMMC disaggregations were collected.

The disaggregations reported for VMMCs performed, and definitions where needed, are listed in table 1. Their rationales and context are summarized below. Not all sites are able to collect and report circumcision data by each disaggregate for all clients. Therefore, percentages presented here for each disaggregate are calculated only among clients for whom data on that disaggregate were reported.
Table 1: Disaggregations and Categories for PEPFAR-supported VMMC program reporting on VMMCs performed, 2016

<table>
<thead>
<tr>
<th>Disaggregation</th>
<th>Client Categories</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>- &lt; 61 days (early infant male circumcision)</td>
</tr>
<tr>
<td></td>
<td>- 2 months-&lt;10 years (not funded by PEPFAR due to safety concerns)</td>
</tr>
<tr>
<td></td>
<td>- 10-14 years (this and younger categories are collapsed here as ‘&lt;15’)</td>
</tr>
<tr>
<td></td>
<td>- 15-19 years</td>
</tr>
<tr>
<td></td>
<td>- 20-24 years</td>
</tr>
<tr>
<td></td>
<td>- 25-29 years</td>
</tr>
<tr>
<td></td>
<td>- 30-49 years</td>
</tr>
<tr>
<td></td>
<td>- 50+ years</td>
</tr>
<tr>
<td><strong>Result of HIV test offer at VMMC site</strong></td>
<td>- HIV+</td>
</tr>
<tr>
<td></td>
<td>- HIV -</td>
</tr>
<tr>
<td></td>
<td>- Unknown: includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason</td>
</tr>
<tr>
<td><strong>Technique</strong></td>
<td>- Surgical</td>
</tr>
<tr>
<td></td>
<td>- Device-based</td>
</tr>
<tr>
<td><strong>Follow-up visit attendance</strong></td>
<td>- Returned for at least one post-operative follow-up visit within 14 days of surgery</td>
</tr>
<tr>
<td></td>
<td>- Did not return within 14 days</td>
</tr>
</tbody>
</table>

1) **Client age range**: Age ranges represent those selected for PEPFAR routine reporting to support fine analysis of client age patterns. PEPFAR’s prioritization of, or “age pivot” to, the 15-29 year age range began in fiscal year 2016. Ages below 15 years constitute the largest combined proportion of VMMCs performed, but will have delayed impact on the HIV epidemic due to the delay until sexual debut and other risk behaviors. These age ranges are collapsed together in this report.

2) **Result of HIV test offer at VMMC site**: Under PEPFAR\(^{16}\), UNAIDS\(^{17}\) and WHO\(^{18}\) guidance active in 2016, HIV testing at the VMMC site should be encouraged but is not required for access to VMMC, and clinically eligible clients who do test may proceed with VMMC regardless of their results. As a disaggregation within the cohort of clients receiving VMMC, this reporting does not include men who were tested at VMMC sites but then decided against VMMC after receiving a positive HIV test result. This may not be unusual, as men testing
positive are counseled that circumcision will not affect the course of their HIV infection and may choose not to proceed.

3) **Circumcision technique used:** Circumcision devices offer an alternative to surgery, and advantages include faster procedures and potentially avoiding the injection of anesthesia and incision of living tissue. Initially, PEPFAR-supported circumcision was exclusively surgical, using one of three WHO-recommended techniques: forceps-guided, dorsal slit, and sleeve resection. With WHO prequalification of the PrePex device in 2013 and ShangRing in 2015, some ministries of health have introduced device-based services as additional options for clients. Both PrePex and ShangRing devices remain on the penis for seven days and are removed by a provider during a follow-up visit. Anatomic and age-based eligibility criteria vary between devices and can be stricter than surgical eligibility criteria, restricting the pool of eligible clients. Numbers of circumcisions performed using a device therefore reflect national policies and eligibility for, as well as availability and client uptake of, these alternative methods. They also reflect the impact of tetanus mitigation policies as discussed below.

4) **Follow-up visit attendance:** PEPFAR-supported programs follow fixed schedules for routine postoperative follow-up set by national ministries of health to ensure client safety. These often include a return visit at days two and seven after surgery, or day seven after device placement (for device removal). In 2015 and 2016, the PEPFAR follow-up indicator was only reported among surgical cases, which therefore constituted the denominator for determining follow-up percentage; in 2017 it was calculated among all circumcisions. Followup was only reported on if it took place, so that clients who did not follow up cannot be distinguished from those whose followup status is unknown.
Comparison data on country-specific total annual VMMC volume (including both PEPFAR-supported and non-PEPFAR supported procedures) is drawn from the most recent WHO VMMC Progress Brief, covering 2007-2016. Data on PEPFAR’s 2017 country-level VMMC targets is drawn from annual PEPFAR Budget and Target reports.

Patient and public involvement: Because this manuscript reports program data rather than research data, no research question or study design was formulated for data collection. Data collected instead consists of indicators designed to monitor program achievements. VMMC clients were beneficiaries choosing to uptake a public health interventions, not research participants. However, satisfied VMMC clients are sometimes involved in recruiting peers for VMMC. Results are publically available online as referenced above.

RESULTS:

From PEPFAR fiscal year 2007 through 2017, a total of 15,269,720 PEPFAR-supported VMMCs were performed in 14 countries in southern and eastern Africa. From 2010 through 2014, annual VMMC numbers approximately doubled annually, reaching 2,794,808 in 2014. In 2015, 2,573,273 VMMCs were performed, followed in 2016 by 2,290,200; these represented the third- and fourth-highest annual totals. The year 2017 saw an increase to 3,665,866, the highest annual total to date. Over half (54%) of PEPFAR-supported circumcisions performed since the program’s inception were performed in 2015-2017 (Figure 1, Table 2). In 2016, the latest year for which WHO national-level data is available, PEPFAR-supported VMMCs constituted 80% of all VMMCs reported by WHO, and 55% or more of reported VMMCs in each individual country except Rwanda. VMMCs conducted in 2017 achieved 92% (3,664,531/3,665,866) of PEPFAR targets for that year, with nine countries reaching 90% or more of their targets.
Twelve countries provided >85% data completeness across all disaggregations in 2017 for which completeness was calculable. By disaggregate, 3,278,130 clients had age data (387,736 missing = 12%); 3,309,077 had result of HIV test offer (including unknown status; 356,789 missing = 11%); 3,282,987 had technique data (382,879 missing = 12%); of whom 2,736,851 had a reported follow-up within 14 days. Because programs only reported the number of clients who received follow-up in 2017, and did not separately report the number which did not, we are unable to assess completeness for this disaggregate (but see table 2 footnote). Where data completeness for a given disaggregate in a country (sum of all VMMCs across categories for that disaggregate, divided by total VMMCs performed) was less than the 85% threshold we selected for this analysis, values are bolded (Table 3).

In 2017, 48% of VMMC clients were within the 15-29 years age range, to which PEPFAR shifted focus that year, a relatively stable proportion from 46% in 2016 and 48% in 2015. There was wide variation among countries, ranging from 25% in Botswana to 68% in Rwanda. In contrast, 45% of PEPFAR VMMC clients were within the 10-14 years range, representing a stable increase, along with 46% in 2016, from 42% in 2015. Eight countries experienced an increase in the proportion of clients in the 10-14 year age range from 2016 to 2017. This shift was largest in Rwanda (5% to 28%), Botswana (45% to 66%), and Namibia (12% to 34%), all relatively small programs. However other programs, like South Africa, did successfully achieve the reverse (43% in 2017, from 51% in 2016). Countries which had previously shifted in 2016 toward younger clientele included several large programs which also showed decreases in overall achievements in that year, such as Tanzania, South Africa and Zambia, though in the first two cases this trend reversed in 2017.
PEPFAR circumcisions through 2017

Table 2: Annual PEPFAR-funded VMMCs performed by country, 2007-2017, and PEPFAR 2017 VMMC targets*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>5,180</td>
<td>534</td>
<td>0</td>
<td>8,590</td>
<td>12,464</td>
<td>13,893</td>
<td>7,712</td>
<td>24,201</td>
<td>22,645</td>
<td>20,911</td>
<td>95,219</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>0</td>
<td>3,110</td>
<td>8,236</td>
<td>12,445</td>
<td>16,393</td>
<td>11,831</td>
<td>11,307</td>
<td>14,335</td>
<td>13,782</td>
<td>17,184</td>
<td>91,439</td>
</tr>
<tr>
<td>Kenya</td>
<td>45,657</td>
<td>112,574</td>
<td>182,788</td>
<td>214,851</td>
<td>229,390</td>
<td>233,813</td>
<td>264,490</td>
<td>227,272</td>
<td>240,010</td>
<td>1,669,113</td>
<td>1,669,113</td>
</tr>
<tr>
<td>Lesotho</td>
<td>0</td>
<td>0</td>
<td>199</td>
<td>6,971</td>
<td>36,418</td>
<td>39,175</td>
<td>28,909</td>
<td>31,709</td>
<td>25,445</td>
<td>40,573</td>
<td>168,826</td>
</tr>
<tr>
<td>Malawi</td>
<td>0</td>
<td>0</td>
<td>778</td>
<td>13,314</td>
<td>67,384</td>
<td>68,334</td>
<td>90,820</td>
<td>82,381</td>
<td>99,435</td>
<td>109,348</td>
<td>422,446</td>
</tr>
<tr>
<td>Mozambique</td>
<td>0</td>
<td>4,009</td>
<td>18,946</td>
<td>79,002</td>
<td>129,581</td>
<td>160,660</td>
<td>187,186</td>
<td>241,793</td>
<td>315,239</td>
<td>427,536</td>
<td>1,136,416</td>
</tr>
<tr>
<td>Namibia</td>
<td>0</td>
<td>1,229</td>
<td>5,379</td>
<td>6,121</td>
<td>0**</td>
<td>785</td>
<td>9,927</td>
<td>15,116</td>
<td>27,736</td>
<td>34,746</td>
<td>66,410</td>
</tr>
<tr>
<td>Rwanda</td>
<td>0</td>
<td>896</td>
<td>3,922</td>
<td>17,639</td>
<td>36,441</td>
<td>74,803</td>
<td>65,048</td>
<td>50,204</td>
<td>175,902</td>
<td>95,936</td>
<td>424,855</td>
</tr>
<tr>
<td>South Africa</td>
<td>18,100</td>
<td>14,956</td>
<td>72,004</td>
<td>170,849</td>
<td>294,977</td>
<td>327,473</td>
<td>472,047</td>
<td>355,917</td>
<td>460,668</td>
<td>428,486</td>
<td>2,186,991</td>
</tr>
<tr>
<td>Swaziland</td>
<td>3,802</td>
<td>19,728</td>
<td>13,399</td>
<td>14,456</td>
<td>9,708</td>
<td>11,934</td>
<td>12,156</td>
<td>16,003</td>
<td>15,071</td>
<td>18,616</td>
<td>116,257</td>
</tr>
<tr>
<td>Tanzania</td>
<td>262</td>
<td>21,581</td>
<td>117,351</td>
<td>151,915</td>
<td>381,394</td>
<td>554,673</td>
<td>615,089</td>
<td>519,437</td>
<td>696,572</td>
<td>696,449</td>
<td>3,058,274</td>
</tr>
<tr>
<td>Uganda</td>
<td>0</td>
<td>9,052</td>
<td>57,132</td>
<td>352,039</td>
<td>742,978</td>
<td>906,615</td>
<td>466,650</td>
<td>330,343</td>
<td>753,198</td>
<td>1,011,964</td>
<td>3,618,007</td>
</tr>
<tr>
<td>Zambia</td>
<td>0</td>
<td>21,236</td>
<td>63,444</td>
<td>103,517</td>
<td>199,372</td>
<td>239,464</td>
<td>216,394</td>
<td>185,028</td>
<td>323,180</td>
<td>271,260</td>
<td>1,351,635</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>0</td>
<td>9,811</td>
<td>30,608</td>
<td>36,765</td>
<td>88,114</td>
<td>155,778</td>
<td>156,215</td>
<td>159,243</td>
<td>227,299</td>
<td>252,847</td>
<td>863,833</td>
</tr>
<tr>
<td>Total</td>
<td>73,118</td>
<td>218,716</td>
<td>574,186</td>
<td>1,131,900</td>
<td>2,230,075</td>
<td>2,794,808</td>
<td>2,573,273</td>
<td>2,290,200</td>
<td>3,383,444</td>
<td>3,665,866</td>
<td>15,269,720</td>
</tr>
</tbody>
</table>

*Table includes countries with reported data.
PEPFAR circumcisions through 2017

* Fiscal years

** PEPFAR support for VMMC in Namibia was paused for strategic planning in 2013.
PEPFAR circumcisions through 2017

Table 3: Numbers and Characteristics of PEPFAR-funded Voluntary Medical Male Circumcisions, Fiscal Year 2017 (Oct. 1, 2016-Sept 30, 2017) by country and 2015-2016 totals

<table>
<thead>
<tr>
<th>Country</th>
<th>VMMCs</th>
<th>Client Age Range in Years (%)</th>
<th>Result of HIV test offer at VMMC site (%)</th>
<th>Technique: Device Method Used (%) (vs. Surgical)</th>
<th>Follow-up Visit Attendance **(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;15</td>
<td>15-19</td>
<td>20-24</td>
<td>25-29</td>
<td>30-49</td>
</tr>
<tr>
<td>Botswana</td>
<td>22,645</td>
<td>66</td>
<td>10</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>13,782</td>
<td>47</td>
<td>26</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>Kenya</td>
<td>227,272</td>
<td>60</td>
<td>23</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Lesotho</td>
<td>25,445</td>
<td>56</td>
<td>18</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Malawi</td>
<td>99,435</td>
<td>42</td>
<td>28</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Mozambique</td>
<td>315,239</td>
<td>45</td>
<td>30</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Namibia</td>
<td>27,736</td>
<td>34</td>
<td>36</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>Rwanda</td>
<td>175,902</td>
<td>28</td>
<td>48</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>South Africa</td>
<td>460,668</td>
<td>43</td>
<td>22</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>Swaziland</td>
<td>15,071</td>
<td>54</td>
<td>29</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Tanzania</td>
<td>696,572</td>
<td>46</td>
<td>26</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>Uganda</td>
<td>753,198</td>
<td>46</td>
<td>26</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Zambia</td>
<td>323,180</td>
<td>38</td>
<td>37</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>227,299</td>
<td>47</td>
<td>25</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Total in 2017</td>
<td>3,383,444</td>
<td>45</td>
<td>27</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Total in 2016</td>
<td>2,290,141</td>
<td>46</td>
<td>27</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>Total in 2015</td>
<td>2,573,238</td>
<td>42</td>
<td>28</td>
<td>13</td>
<td>7</td>
</tr>
</tbody>
</table>

**Bolded** entries indicate <85% data completeness.

* Includes clients with undocumented or indeterminate status and those not tested at the VMMC site for any reason

** Percent of clients who returned for at least one post-operative follow-up visit within 14 days of surgery or device placement

*** Followup rate in Zimbabwe unknown for 2017. Facilities representing 46% of all Zimbabwe circumcisions did not report followup data, due to delays in adoption of the new follow-up reporting method.
PEPFAR circumcisions through 2017

Overall, 8% of clients had “unknown” HIV status in 2017, as compared to 9% in 2016 and 7% in 2015, with individual country values ranging from 0% in Rwanda and Zimbabwe to 50% in Lesotho; other countries with high “unknown” rates were Ethiopia at 32% and Namibia at 44%. Among clients tested for HIV, 1% were positive, essentially unchanged from 2015-2016, with individual country positivity varying between 0% in Zimbabwe, Tanzania, Mozambique and Ethiopia, and 5% in Malawi.

Device-based circumcision techniques constituted a small percentage of circumcisions in all countries in 2017, accounting for 3% of VMMCs across countries (down from 5% in 2015 and 4% in 2016), ranging between 0% in many countries and 53% in Rwanda. Botswana and Zimbabwe showed substantial respective drops from 28% to 0% and 27% to 5%.

Post-procedure follow-up rates among all clients were 84% overall (excluding Zimbabwe), higher than the 72% in 2015 and 78% in 2016. These rates ranged between 59% in South Africa and 100% in Rwanda, falling at or above 75% in 11 countries.

DISCUSSION:

VMMC has undergone a scale-up of historic proportions within global health, comparable to the scale-up of HIV treatment. This manuscript demonstrates that overall program volume is high and increasing, but there is progress to be made in increasing volume further to pursue Fast Track targets, attracting older clients with higher HIV risk and, in some places, raising postoperative follow-up rates to ensure complications are managed promptly.
PEPFAR circumcisions through 2017

With respect to program volume, over 15 million PEPFAR-supported VMMCs were performed between 2007 when support began and 2017, making VMMC a major prevention intervention for achieving the PEPFAR goal of an AIDS-free generation through epidemic control in sub-Saharan Africa.\textsuperscript{25} PEPFAR had committed in 2015 to supporting at least 13 million VMMCs through 2017,\textsuperscript{26} and exceeded that target. Models estimate that global VMMCs conducted through 2016 alone will avert 500,000 infections by the end of 2030.\textsuperscript{14} Scale-up has been enabled not only by dedicated resources, totaling over $1.5 billion through 2017 from PEPFAR alone, but also through leadership from ministries of health, rapid expansion of surgical skills and responsibilities to non-physician health cadres, and public outreach campaigns. It has provided millions of men with lifelong partial protection from HIV and some STIs, and connected them with additional HIV and other health services through testing, STI screening, and referrals for other health conditions. Infections averted in men through VMMC also help prevent new HIV infections among women and girls,\textsuperscript{27,28,29} and male circumcision is also associated with lower prevalence of a range of STIs in women.\textsuperscript{29}

In light of the high proportion of global VMMCs supported, PEPFAR client data is also expected to provide a reasonably representative view of the global VMMC clientele to date. References to achievements and characteristics below refer to the PEPFAR program except where otherwise stated.

All VMMC implementing countries continue to scale up VMMC. However, in 2015 and 2016 there were substantial declines in PEPFAR VMMC achievements in Uganda (the largest contributor to VMMC results); these were mirrored by declines in total VMMCs achieved in Uganda.\textsuperscript{14} Service delivery and policy were impacted by the identification of tetanus as a risk among VMMC clients in the Ugandan setting, due to limited historical tetanus immunization coverage.\textsuperscript{30,31,32} WHO issued global recommendations that additional visits for tetanus vaccination be performed prior to circumcision using
device-based VMMC methods associated with increased risk of tetanus,\cite{33} and the Uganda National VMMC Program ultimately required an additional visit for tetanus vaccination prior to VMMC. Similar policies may have also impacted performance in other countries with significant device contributions (not shown) like Botswana and Rwanda. Additionally, a PEPFAR policy issued in late 2014 discontinued the use of the forceps-guided surgical technique in young adolescents to avoid the associated risk for injury to the immature glans, causing some country programs to decrease VMMC provision to this age range until they could retrain their VMMC workforces in a more appropriate method. In 2016, Tanzania, South Africa and Zambia also experienced declines (Uganda had not previously reported age data), though these were accompanied by increases in client proportions in the 10-14 age group, and were followed in 2017 by increases in overall performance and shifts toward older clientele. These 2016 declines may thus be due to strategic shifts in program geography and funding. Total program performance then increased substantially in 2017, with nine countries showing increases over 2016, including these largest programs. We attribute this recovery to resolution of the challenges described above, combined with increases in available resources.

Country-level PEPFAR VMMC targets are set each year for the following year, based on previous years’ achievements, available resources, overall ministry of health targets, and remaining unmet need to achieve saturation. In 2017, overall performance was well-matched to targets (92%), with variations including some countries with marked overperformance (Rwanda and Zambia) and others with high absolute performance but even more ambitious targets (e.g. Uganda, with the highest national PEPFAR VMMC performance ever reported). In addition to the policy factors discussed above, reasons for variation in performance against targets can include implementing partner capacity and
PEPFAR circumcisions through 2017

ambition (partners may choose to surpass their targets once achieved, if funding remains) and unexpected external factors such as civil unrest and health care strikes.

VMMC client populations in 2017 were young, with males in the 10-14 years age range representing 45\% of all PEPFAR VMMCs (virtually all VMMCs in clients <15 years are in the 10-14 year range), as compared to 12\% of the combined male general population of the 14 implementing countries.\(^{34}\) This represents a change from the program’s historical client age distribution; from 2010 through 2013, clients in the 10-14 years age range characterized no more than one third of all clients in any year.\(^{35}\) The 2015 distribution (42\% of clients were aged <15 years) served as the baseline prior to implementation of the “age pivot”; yet the actual age balance shifted further toward the younger range in 2016 (46\%), with only slight recovery in 2017, despite this focus. In some countries, the shift toward younger ages may partially reflect the maturation of the VMMC program: ‘exhaustion’ of older age ranges and replacement with younger males. Additional potential barriers which may apply disproportionately to older males include reluctance to abstain from sex for the 6-week healing period, perception of low risk due to having established partners, the opportunity cost of lost wages during recovery, and fear of creating perceptions in a stable partner that they intend to seek other sexual partners.\(^ {36,37}\) Age ranges 30 years and above represented a small (8\% in 2017) percentage of VMMC clientele, despite being a sexually active group at risk for HIV, possibly for similar reasons. However, some countries and individual partners did successfully make modest shifts toward older clientele, and identification and broader adoption of their best practices are called for.

VMMC clients also have low HIV positivity compared to the general population, 1\% among all clients in 2015, 2016 and 2017, as compared to 5.5\% (95\% confidence interval 4.9-6.0\%) prevalence among males aged 15-49 years in the southern and eastern Africa region in 2016.\(^ {38}\) The young age of
PEPFAR circumcisions through 2017

the client population is almost certainly the major underlying factor; pre-adolescents and early adolescents have less exposure to sex and consequently less HIV risk and lower HIV prevalence than older age groups. Because HIV test results are not disaggregated by age group, this effect cannot be controlled for in PEPFAR VMMC reporting data. Lower HIV prevalence among VMMC clients could also reflect self-selection of men with health-protecting behaviors into the pool of VMMC clients and/or the effects of messaging promoting VMMC for HIV prevention, leading to the self-exclusion of men who know they are HIV-positive (including any who learn they are HIV-positive at the VMMC site and consequently opt out of VMMC). Despite this low prevalence, it should be noted that men in sub-Saharan Africa have lower HIV testing uptake than women and the VMMC program provides an opportunity to reach men who might not otherwise undergo testing. The substantial proportion of clients with ‘unknown’ test results is expected, and may reflect the voluntary nature of HIV testing in VMMC, as well as the frequency of HIV test kit stockouts (e.g., Ethiopia and Namibia experienced intermittent stockouts in 2017).

The fact that few circumcisions were performed by device methods throughout 2015-2017 reflects in part the relatively short period that device-based circumcision has been available, as well as the rigorous country-level vetting process which new devices undergo when being introduced in a new country, prior to nationwide rollout. It may also reflect current preferences of clients and programs. As of publication, all countries implementing PEPFAR-supported VMMC except Ethiopia and Namibia have begun the evaluation process for at least one device, although scale-up of device-based service delivery can take time even after evaluation is completed and policy is in place. Although devices offer several advantages over surgical circumcision, they require more intense post-market safety monitoring tailored to their mechanisms of action, until more VMMCs have been done using these methods. Most
PEPFAR circumcisions through 2017

recently, uptake of the most commonly-used device has also been negatively impacted by the WHO advice and PEPFAR policy related to tetanus vaccination prior to device placement,\(^{41}\) driving the decline noted from 2015-2017.

Although the follow-up rate of 84% in 2017 is not precisely comparable to rates in 2015 and 2016 because of the inclusion of device followup, the low proportion of the program represented by device MCs makes the apparent increase likely to constitute a true trend. Followup is also likely to be underestimated, because all clients without a reported followup visit were treated in calculations as not following up, rather than missing data. This is encouraging, but more remains to be done in countries with low follow-up rates. There is evidence that adverse events (AEs) are actually more common among males who do not return for follow-up than among those who do.\(^{42}\) While VMMC is extremely safe,\(^{43}\) achieving high follow-up rates to allow early AE diagnosis and intervention is crucial for program safety.

The findings in this paper are subject to several limitations. These data reflect results supported by PEPFAR, rather than country totals. Additionally, cross-tabulations between disaggregations are not reported, and therefore it is not possible to determine associations between age range, result of HIV test offer and procedure technique, or control for measured potential confounders. For reasons discussed above, VMMC clients are not representative of the general male population of their countries; they are younger, less likely to be HIV-positive, and possibly at lower behavioral risk; findings here are not intended to be generalized outside the client population. Data entry errors such as those discussed above for follow-up, and variations in reporting practice, are possible. Category definitions combine some disparate groups (e.g. “unknown” test results include men who were not tested at VMMC sites for any reason, whether preference, test kit shortage, or documentation of recent outside testing.) Finally, though
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
PEPFAR circumcisions through 2017

**FUNDING:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sections. It was supported in part by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).

**COMPETING INTERESTS:** Authors declare no competing interests.

**DISCLAIMER:** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies, the Centers for Disease Control and Prevention, the US Agency for International Development, or the United States Government.

**CONTRIBUTORSHIP:** Stephanie M. Davis drafted and finalized the manuscript.

Jonas Hines, Melissa Habel, Jonathan M. Grund, Renee Ridzon, Jonathan Davitte, Anne Thomas, Valerian Kiggundu, Caroline Cooney, and Naomi Bock revised the manuscript.

Brittney Baack and Paran Pordell revised the data and manuscript.

Carlos Toledo conceived of the paper, obtained the data, and revised the manuscript.

Irum Zaidi oversaw all data collection.

**DATA SHARING:** As described in this article, the dataset underlying the tables and results is publically available at [https://data.pepfar.net/quarterlyData/](https://data.pepfar.net/quarterlyData/).

**ETHICAL STATEMENT:** Use of this routinely collected, aggregate-only program data was reviewed and approved by CDC Human Subjects Protection.

**RESEARCH REPORTING CHECKLISTS:** Because this manuscript is based on routinely collected program data and does not examine associations between risk factors and outcomes, none of the
PEPFAR circumcisions through 2017

standard checklists are entirely applicable, including per EquatorWizard. At the editors’ request, the STROBE checklist has been filled and included with resubmission.
PEPFAR circumcisions through 2017

Figure Legend

Figure 1: Cumulative Number of PEPFAR-supported Voluntary Medical Male Circumcisions by Country, 2007-2017
PEPFAR circumcisions through 2017

REFERENCES


PEPFAR circumcisions through 2017


PEPFAR circumcisions through 2017


30 Uganda Ministry of Health. Memo Re: The need for tetanus vaccination for men undergoing circumcision and the continued scale-up of safe male circumcision using PrePex.” December 30, 2015.


PEPFAR circumcisions through 2017


Figure 1: Cumulative Number of PEPFAR-supported Voluntary Medical Male Circumcisions by Country, fiscal years 2007-2017

152x95mm (300 x 300 DPI)
### STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract – pg 1 (page numbers are for clean version)  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found – pg 2 |
| **Introduction** | 2 Explain the scientific background and rationale for the investigation being reported – pg 4-6 |
| **Objectives** | 3 State specific objectives, including any prespecified hypotheses – pg 5 |
| **Methods** | 4 Present key elements of study design early in the paper – pg 5 |
| | 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – pp 4-6 |
| | 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants – pg 5 |
| **Variables** | 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable – pg 7 |
| **Data sources/ measurement** | 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group – pg 7 |
| **Bias** | 9 Describe any efforts to address potential sources of bias – pg 18 (this is a limitation of the way program data is collected) |
| **Study size** | 10 Explain how the study size was arrived at – pg 5 (all clients – program data) |
| **Quantitative variables** | 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why – pg 7-10 |
| **Statistical methods** | 12 (a) Describe all statistical methods, including those used to control for confounding – pg 6-8, 18  
(b) Describe any methods used to examine subgroups and interactions - N/A (no subgroups, no interactions)  
(c) Explain how missing data were addressed – pg 6, 10  
(d) If applicable, describe analytical methods taking account of sampling strategy (N/A)  
(e) Describe any sensitivity analyses (N/A) |
| **Results** | 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed - pg 10 provides total numbers, but there are no exclusion stages for program data like those described above  
(b) Give reasons for non-participation at each stage - N/A  
(c) Consider use of a flow diagram - N/A |
| **Descriptive data** | 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders – pg 12  
(b) Indicate number of participants with missing data for each variable of interest – pg 11 |
| **Outcome data** | 15* Report numbers of outcome events or summary measures – pg 12 |
### Main results

16  

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included – pg 12 (confidence intervals are not applicable because the data represents a census of the client population rather than a sample, and is not being extrapolated to any larger population), 17  

(b) Report category boundaries when continuous variables were categorized – pg 7  

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period – N/A

### Other analyses

17  

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses – N/A

### Discussion

| Key results | 18  | Summarise key results with reference to study objectives – pp13-18 |
| Limitations | 19  | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – pp 18-19 |
| Interpretation | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – pp 13-18 |

**Generalisability** 21  

Discuss the generalisability (external validity) of the study results – pg 19

### Other information

| Funding | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – pg 20 |

*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.